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Abstract 
The MdfA is a 410 amino acid-long integral membrane protein, which belongs to the 
Major Facilitator superfamily of multidrug transporters.  It is predicted to consist of 12 
transmembrane helices.  MdfA uses the energy of the transmembrane proton gradient to pump a 
variety of toxic compounds out of E. coli cells.  No high resolution structure of MdfA is 
available.  The goals of this research project were to develop a practical method for purification 
of MdfA, to evaluate the feasibility of structure determination by Nuclear Magnetic Resonance 
(NMR) and X-ray crystallography, and to develop an activity assay for purified MdfA.  To this 
end, MdfA, with a hexa-histidine tag attached to facilitate protein purification, was successfully 
expressed and incorporated into the cell membrane using an E. coli expression system.  MdfA 
was extracted from the cell membrane with the detergents 1,2-diheptanoyl-sn-glycero-3-
phosphocholine (DHPC), n-dodecyl--D-maltoside (DDM), and 1-myristoyl-2-hydroxy-sn-
glycero-3-[phospho-rac-(1-glycerol)] (LMPG) and purified by affinity chromatography on 
nickel-nitrilotriacetic acid agarose.  Pure protein was found to be monodisperse in DHPC, 
DDM and LMPG micelles.  To achieve simple amino acid selective isotope labeling for high-
resolution NMR studies, MdfA was expressed in a cell-free translation system.  To determine if 
the purified protein was properly folded, 
19
F NMR experiments were carried out on 5-fluoro-
tryptophan-labeled MdfA while titrating the MdfA substrates ethidium bromide and 
chloramphenicol into the fluoro-tryptophan-labeled MdfA sample.  An activity assay was 
developed for MdfA incorporated into liposomes using the fluorescent dye 9-amino-6-chloro-2-
methoxyacridine (ACMA) to detect proton translocation coupled to substrate transport.  Results 
from both the 
19
F NMR and the transport activity assay indicated that the purified MdfA was 
properly folded and functional.  NMR experiments with pure MdfA yielded spectra of 
insufficient quality for high-resolution structure determination but did indicate that structural 
studies of MdfA by NMR are feasible.  Crystallization trials yielded crystals that are likely to 
contain protein and will serve as a starting point for further optimization of crystallization 
conditions for X-ray structure determination.  
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1. Introduction 
 The ability of an organism to withstand the effects of a variety of toxic compounds is 
known as multidrug resistance.  Multidrug resistance can be the result of over-expression of 
multidrug transporting proteins.  Multidrug transporters are a family of membrane proteins that 
recognize a broad range of substrates and facilitate their movement out of the cell.  Multidrug 
transporters are found in both prokaryotic and eukaryotic organisms.  
Multidrug resistance due to over-expression of multidrug transporters is becoming a 
major problem in modern medicine.  Bacterial infections that were once easy to treat with 
antibiotics are now more resilient due to the emergence of multidrug resistance.  Staphylococcus 
aureus is one such bacterium that was previously treatable with penicillin, but is now resistant 
not only to penicillin, but to many other antibiotics as well, including methicillin and vancomycin 
(Jevons, 1961; Hiramatsu et al., 1997; Howe et al., 1998; Ploy et al., 1998).  Staphylococcus 
aureus is commonly found on the skin, but if internalized through skin abrasions, it can cause 
skin boils, pressure sores, blood poisoning (septicemia), pneumonia, or bone, joint, and heart 
valve infections.  In 2005 in the United States, 477,927 people were hospitalized with 
Staphylococcus aureus infections and there were 11,406 Staphylococcus aureus-related deaths 
(Klein et al., 2007).  NorA is an example of a multidrug transporter found in Staphylococcus 
aureus which confers resistance to the quinolones norfloxacin, enoxacin, ofloxacin, 
ciprofloxacin, nalidixic acid, oxolinic acid, and sparfloxacin (Yoshida et al., 1990).   
Mycobacterium tuberculosis is another example of a bacterium that has developed 
resistance to several different antibiotics.  Drug-resistant tuberculosis is one of the most deadly 
and common infectious diseases, claiming millions of lives per year worldwide (World Health 
Organization Report, 2008).  Drug-resistance in tuberculosis can be acquired by several 
mechanisms, one being drug extrusion by multidrug transporters.  DrrAB is an example of a 
multidrug transporter expressed in Mycobacterium tuberculosis that has been found to confer 
resistance to a broad range of clinically relevant antibiotics including tetracycline, erythromycin, 
ethambutol, norfloxacin, streptomycin and chloramphenicol (Choudhuri et al., 2002).  These are 
just two examples of bacterial infections that, due to multidrug resistance, are no longer as easily 
treatable using antibiotics as they once were. 
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Human diseases such as cancer, epilepsy, and acquired immunodeficiency syndrome 
(AIDS) are becoming very hard to treat due to the over-expression of the human multidrug 
transporter P-glycoprotein.  P-glycoprotein binds and expels many chemotherapeutic drugs used 
in the treatment of cancers and AIDS (Juliano and Ung, 1976; Chen et al., 1986; Ueda et al., 
1987; Endicott and Ling, 1989; Higgins, 1992; Gottesman and Pastan, 1993; Lee et al., 1998; 
Krishna and Mayer, 2000; Gottesman et al., 2002), as well as antiepileptic drugs (Loscher and 
Potschka, 2002; Siddiqui, 2003).  Not only do multidrug transporters interfere with the treatment 
of bacterial infections, but also with the treatment of non-bacterial diseases. 
A simple experimental model is required to better understand how multidrug transport 
proteins work.  For this study, we chose the multidrug transport protein MdfA, which is found in 
Escherichia coli (E. coli).  The ultimate goal of this research project is to elucidate the molecular 
mechanism of drug extrusion catalyzed by MdfA and similar transport proteins.  To this end, we 
expressed and purified MdfA for structural studies and evaluated the feasibility of solving the 
three-dimensional structure of MdfA by Nuclear Magnetic Resonance (NMR) and X-ray 
crystallography.  A high-resolution structure of MdfA could aid the development of novel means 
of antimicrobial therapy, and overcome drug resistance in bacterial infections and cancer.  
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2. Background and State of the Problem 
2.1. Mechanisms of Antibiotic Resistance 
The four main mechanisms by which bacteria can acquire drug resistance are: drug 
inactivation; alteration of drug target; alteration of the targeted metabolic pathway; and reduced 
drug accumulation (Tenover, 2006).    
The first mechanism involves chemical modification of the drug molecule by an 
enzymatic reaction resulting in drug inactivation.  An example of this mechanism is inactivation 
of penicillins by -lactamase.  Penicillins achieve antibiotic activity through their interactions 
with transpeptidases, also known as penicillin-binding proteins (Wise and Park, 1965).  
Transpeptidases are responsible for the formation of cross-links in the peptidoglycan layer.  The 
lactam ring of penicillins binds the active sites of transpeptidases, inactivating the enzyme and 
preventing cross-linking of the peptidoglycan, which disrupts synthesis of the peptidoglycan 
layer.  First discovered in 1940 (Abraham and Chain, 1940), -lactamase hydrolyzes the lactam 
ring of penicillins.  Hydrolysis of the lactam ring abrogates its antimicrobial activity.  
The second mechanism is the alteration of the antibiotic target site in such a way that the 
drug no longer interacts with the target, thereby losing its effectiveness.  An example of this 
mechanism is found in Staphylococcus pneumoniae which developed altered forms of penicillin-
binding proteins with decreased affinity for penicillins (Laible and Hakenbeck, 1991).  This 
allows transpeptidation of the peptidoglycan layer to proceed even in the presence of penicillin. 
The third mechanism occurs when bacteria develop an alternative metabolic pathway that 
bypasses the target protein of the drug.  E. coli infections, as well as other infections caused by 
Gram-negative bacteria, have been found to exhibit resistance to trimethoprim by bypassing the 
folic acid metabolic pathway (King et al., 1983).  Trimethoprim achieves its antibiotic activity by 
competitively inhibiting dihydrofolate reductase, an enzyme, which is critical for the biosynthesis 
of folic acid.  E. coli has been found to be resistant to trimethoprim by becoming dependent on an 
external supply of thymine, which is normally synthesized from folic acid (King et al., 1983).     
The last mechanism, reduced drug accumulation, is achieved by either limiting drug 
entrance into the cell, or by actively pumping the drug out of the cell.  As an example, 
tetracycline resistance in E. coli is conferred by actively pumping the drug out of the cell.  
Tetracycline achieves antibiotic activity through the binding of 16S rRNA which prevents the 
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attachment of aminoacyl-tRNA to the ribosomal acceptor site, thus inhibiting protein synthesis.  
TetA is a metal-tetracycline/proton antiporter, which actively pumps tetracyclines out of the cell 
leading to E.coli resistance to tetracycline (Yamaguchi et al., 1990).    All multidrug transporters 
use this fourth mechanism to achieve antibiotic resistance.  
2.2. Bacterial Multidrug Transporters 
 Multidrug transporters are a family of membrane proteins found in many different 
organisms that recognize a broad range of substrates and facilitate their subsequent movement 
across the cell membrane.  Multidrug transporters are divided into five families: adenosine 
triphosphate (ATP)-binding cassette (ABC) superfamily (Fath and Kolter 1993; Higgins, 2001), 
multidrug and toxic compound extrusion (MATE) family (Brown et al., 1999), small multidrug 
resistance (SMR) family (Paulsen et al., 1996b), resistance-nodulation-cell division (RND) 
family (Saier et al., 1994), and major facilitator superfamily (MFS) (Pao et al., 1998) (Figure 
2.1). 
 All of these multidrug transporters can be divided into two main groups, primary and 
secondary active transporters, depending on the driving force of the substrate transport.  Primary 
active transporters use the energy released by ATP hydrolysis to transport their substrates, 
whereas secondary active transporters use electrochemical ion gradients to drive their substrate 
transport.  The ABC transporters is the only family that is classified as a primary active 
transporter type, whereas the other families, MFS, RND, MATE, and SMR, are classified as 
secondary active transporters.    
The ABC transporters have been found to transport sugars, amino acids, ions, drugs, iron 
complexes, polysaccharides and proteins across the cell membrane (Higgins, 1992; Fath and 
Kolter, 1993; Saier et al., 1999).  They are the largest multidrug transporters due to their bulky 
ATP binding domains.  The large ATP binding domain can be observed in the X-ray structure of 
the ABC transporter Sav1866 from Staphylococcus aureus in Figure 2.2.  This protein functions 
as a homodimer where each monomer consists of 6 transmembrane helices and an ATP binding 
domains.  The ATP binding domain is a very large and complex portion of the ABC transporters, 
which in turn can complicate structural studies in both NMR and X-ray crystallography.  
Therefore, a smaller secondary active transporter lacking the ATP binding domain, such as 
MdfA, would be a simpler model protein for structural studies.  
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Figure 2.1.  The five multidrug transporter families. Reprinted with permission from Macmillan 
Publishers Ltd: (Nature) (Krulwich et al., 2005). 
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Figure 2.2.  Side view of the three dimensional structure of the ABC transporter Sav1866 with 
the subunits colored yellow and turquoise.  TMDs: transmembrane domains; NBDs: nucleotide-
binding domains.  Reprinted with permission from Macmillan Publishers Ltd: (Nature) (Dawson 
and Locher, 2006) (PDB ID 2ONJ). 
 
The members of the MATE family of multidrug transporters have been found to 
mediate resistance to cationic dyes, aminoglycosides, and fluoroquinolones.  Unlike the ABC 
transporters, MATE transporters use proton and sodium electrochemical gradients as driving 
forces of transport (Morita et al., 1998, 2000).  MATE family members are similar to MFS 
family members because they contain 12 transmembrane helices, but they do not exhibit 
sequence similarity with any members of the MFS (Morita et al., 1998).   
The transporters of the SMR protein family also pump drugs out of the cell in 
exchange for protons.  SMR proteins are much smaller than other multidrug transporters, 
about 110 amino acid residues in length, and typically consist of four transmembrane helices.  
They also have a smaller substrate range, usually limited to lipophilic cations (Grinius et al., 
1992; Schuldiner et al., 1997).  EmrE, a member of the SMR family, is an asymmetric dimer 
where each monomer contains four transmembrane helices (Figure 2.3).  The EmrE dimer 
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confers resistance to toxic poly-aromatic cations.  The structure for EmrE purified using the 
detergent dodecylmaltoside was originally solved using cryo-electron microscopy (cryo-EM) 
(Figure 2.3, A).  A subsequent X-ray structure was found to be similar to the cryo-EM 
structure (Figure 2.3, B), having a pairwise root mean square difference (RMSD) of 1.4 
Ångstrom over the equivalent C

 atoms (Chen et al., 2007).    
 
Figure 2.3.  Top down view of the three dimensional structure of EmrE solved by cryo-
electron microscopy (A) (Tate, 2006) (PDB ID 2I68) and X-ray crystallography (B) (Chen et 
al., 2007) (PDB ID 3B5D).  Tetraphenylphosphonium is represented by a space-filling model 
in A and is pointed to in B (red arrow).  Reprinted with permission from Elsevier. 
 
 
 
 
 
A     B 
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The RND family members usually form complexes with membrane fusion proteins 
and outer membrane components to allow drug transport across both the inner and outer 
membranes of gram-negative bacteria.  The RND-type efflux proteins are mostly drug/proton 
antiporters consisting of 12 transmembrane helices (Saier et al., 1994).  They recognize a 
variety of clinically relevant antimicrobials such as carbenicillin, thiolactomycin, tetracycline, 
and chloramphenicol (Nikaido, 1998).  The E. coli AcrB transporter functions as a 
homotrimer, wherein each subunit contains 12 transmembrane helices and two large 
periplasmic domains as shown in Figure 2.4.  The two large periplasmic domains are a pore 
domain and what is believed to be a TolC docking domain.  AcrB is hypothesized to be in a 
multi-protein complex with the outer membrane channel protein TolC and the periplasmic 
linker protein AcrA (Figure 2.5) (Murakami et al., 2002).  This structure allows for the direct 
export of drugs from the cell interior to the external medium. 
 
 
Figure 2.4.  Side view of the three dimensional structure of AcrB.  Red, green and blue 
represent the three individual protomers. Reprinted with permission from Macmillan 
Publishers Ltd: (Nature) (Murakami et al., 2002) (PDB ID 1IWG). 
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Figure 2.5.  Side view of the proposed model for the AcrB-AcrA-TolC complex. Reprinted 
with permission from Macmillan Publishers Ltd: (Nature) (Murakami et al., 2002) (PDB ID 
1IWG). 
 
 
The MFS transporters facilitate the transfer of sugars, anions, metabolites, and drug 
molecules across the cell membrane, driven by ion electrochemical gradients, typically 
proton-motive force (Marger and Saier, 1993; Pao et al., 1998; Saier et al., 1999).  The Major 
Facilitator Superfamily consists of sugar uptake facilitators (Maiden, et al., 1987; Henderson 
and Maiden, 1990), multidrug transporters such as EmrD of E. coli (Naroditskaya, 1993), 
single drug transporters such as Tet (L) of Bacillus subtilis (Krulwich et al., 2001), Krebs 
cycle intermediate transport facilitators (Griffith et al., 1992; Paulsen and Skurray, 1994), 
organophosphate:phosphate exchangers, and oligosaccharide:H
+
 symporters (Marger and 
Saier, 1993).  The MFS transporters can be further classified into two families based on 
transmembrane topology.  While MFS transporters with 14 transmembrane helices are 
classified under the DHA14 family, MFS transporters with 12 transmembrane helices are 
classified under the DHA12 family (Paulsen et al., 1996a; Pao et al., 1998).
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GlpT and LacY are two DHA12 MFS transporters from E. coli whose three 
dimensional structures have been solved by X-ray crystallography to 3.3 and 3.5 Ångstrom 
resolution respectively (Abramson et al., 2003; Huang et al., 2003).  GlpT facilitates the 
transport of glycerol-3-phosphate in exchange for organic phosphate while LacY facilitates 
the transport of lactose using the proton gradient.  A central cavity opening into the cytosol is 
seen both in GlpT and LacY when the substrate is not present (Figure 2.6 and 2.7).  LacY has 
been studied in depth, which resulted in the determination of the amino acids involved in 
substrate binding (Glu
126
, Arg
144
, Trp
151
 and Glu
269
), as well as in proton translocation (Tyr
236
, 
Glu
269
, Arg
302
, His
322
 and Glu
325
) (Abramson et al., 2003).  The substrate binding site for 
GlpT is believed to be deep in the internal cavity and to contain two positively charged 
residues, Arg
45
 and Arg
269
 (Huang et al., 2003).  These two MFS transporters share similar 
overall structure, having an RMSD of 3.7 Ångstrom (Vardy et al., 2004). 
In order to treat patients with multidrug resistant bacterial infections that express one 
or several multidrug transporters, it is critical that multidrug transporters are studied in detail.  
Proteins such as MdfA, which belongs to the MFS transporters, make good candidates for 
structural studies. 
 
 
  
Figure 2.6.  Side view of the ribbon representation of GlpT (Huang et al., 2003) (PDB ID 
1PW4).  Reprinted with permission from AAAS.   
 
 
 
    Periplasm 
 
  Cytoplasm 
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Figure 2.7.  Side view of the ribbon representation of LacY (Abramson et al., 2003) (PDB ID 
1PV6).  -D-galactopyranosyl-1-thiol--D-galactopyranoside is represented by black spheres.  
Reprinted with permission from AAAS. 
 
 
2.3. MdfA, an E. coli Multidrug Transporter with Extremely Broad Substrate 
Specificity 
 MdfA is an E. coli multidrug resistance transporter consisting of 410 amino acids 
(Edgar and Bibi, 1997).  This membrane protein belongs to the Major Facilitator Superfamily 
of secondary transporters (Saier and Paulsen, 2001).  Recent studies have found that MdfA 
operates as a monomer (Sigal et al., 2007).  MdfA facilitates the movement of substrates out 
of the cell in exchange for protons (Edgar and Bibi, 1997; Mine et al., 1998; Lewinson, et al., 
2002).  MdfA translocates an extremely large range of substrates, including various cationic 
or zwitterionic lipophilic compounds, such as ethidium bromide, tetraphenylphosphonium, 
rhodamine, daunomycin, benzalkonium, rifampin, tetracycline, and puromycin (Edgar and 
Bibi, 1997).  Additionally, MdfA can also translocate chemically unrelated antibiotics such as 
chloramphenicol, erythromycin, and certain aminoglycoside and fluoroquinolone molecules 
(Edgar and Bibi, 1997).  MdfA also acts as a K
+
-Na
+
/proton antiporter and confers resistance 
to extreme alkaline pH conditions up to pH 10 (Lewinson et al., 2004).   
Periplasm 
Cytoplasm 
C 
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Limited structural information is available for MdfA through a secondary structure 
model constructed based on its hydropathy profile and the distribution of positively charged 
residues.  MdfA is predicted to contain twelve alpha-helices spanning the plasma membrane 
(Figure 2.8).  The predicted transmembrane topology of MdfA agrees with the X-ray crystal 
structure of the homologous protein, EmrD, which was also found to have 12 transmembrane 
helices (Figure 2.9) (Yin et al., 2006).  MdfA has 26% sequence identity and 39% similarity 
to EmrD and therefore should have a structure similar to EmrD.  The structure for EmrD was 
solved to 3.5 Ångstrom resolution (Yin et al., 2006). 
 
Figure 2.8.  Secondary-structure model for MdfA based on hydropathy profile and 
distribution of positively charged amino acids (Bold) (Adler and Bibi, 2002).  Reprinted with 
permission from the American society of Microbiology.  Glu-26 (circled) has been implicated 
in the binding of cationic substrates.  
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Figure 2.9.  Stereo view of the three dimensional structure of EmrD (Yin et al., 2006) (PDB 
ID 2GFP).  Reprinted with permission from AAAS.   
 
 
The drug extrusion by MdfA is believed to occur via the rocker switch mechanism, 
which is also proposed to function in EmrD, GlpT, LacY, and other MFS transporters (Figure 
2.10) (Abramson et al., 2003; Huang et al., 2003; Yin et al., 2006).  In the rocker switch 
mechanism, the protein starts in a state where the central cavity is open to the cytoplasm.  The 
substrate then enters the central cavity and binds to the protein.  For EmrD, and other proteins 
that transport lipophilic molecules, the substrate can also enter from the inner membrane 
leaflet (Path 1, Figure 2.10) or through the cytoplasm (Path 2, Figure 2.10).  The protein then 
changes conformation coupled with H
+
 antiport, closing the internal cavity to the cytoplasm 
and opening it to the periplasm, which allows the release of the substrate.  The structures for 
GlpT and LacY (Figure 2.6 and 2.7 respectively) show these proteins in the cytoplasm open 
state (A, Figure 2.10), whereas the structure of EmrD (Figure 2.9) shows it in the closed state 
(B, Figure 2.10). 
 
 
 
Cytoplasm Cytoplasm 
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Figure 2.10.  Rocker switch mechanism (Yin et al., 2006).  (A) The substrate enters the 
internal cavity and binds to the active site.  (B)  The protein closes.  (C) The drug is released 
into the periplasm, coupled with proton antiport.  Reprinted with permission from AAAS. 
 
 
The ways in which MdfA recognizes a broad range of substrates can be hypothesized by 
contrasting the homologous protein EmrD with GlpT.  EmrD has a broad substrate range, 
while GlpT transports only inorganic phosphate and organophosphates.  GlpT has two 
positively charged amino acids (Arg
45
 and Arg
269
) involved in substrate binding (Huang et al., 
2003), while EmrD is believed to have seven residues with hydrophobic side-chains involved 
in substrate binging (Ile
28
, Ile
217
, Ile
253
, Tyr
52
, Tyr
56
, Trp
300
, and Phe
249
) (Yin et al., 2006). 
GlpT’s two positively charged Arg side chains electrostatically interact with negatively 
charged phosphate groups, which results in tight and highly specific binding of the substrate 
molecules.  EmrD has several amino acids involved in substrate binding resulting in several 
weaker interactions, probably van der Waals interactions, with the outcome being lower 
binding affinity.  The weak interactions result in lower specificity, and different combinations 
of the interactions can account for recognizing a variety of different substrates.  For example, 
figure 2.11 depicts the binding of three different substrates to the same binding site of the 
transcriptional regulator QacR.  Different combinations of amino acids are involved in the 
binding of the different substrates.  The substrate binding site for MdfA has been implicated 
to contain the amino acids Cys
21
, Glu
26
, Gly
39
, Val
54
, Thr
56
, Ala
128
, Ala
147
, Ala
191
, and Val
335
 
(Edgar and Bibi, 1999; Adler and Bibi, 2004; Adler, et al., 2004), which would allow for the 
recognition of a large range of substrates.   MdfA has only one charged amino acid located 
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within the lipid bilayer, Glu
26
 (Fig 2.8), which has been found through mutagenesis to be 
essential for the recognition and binding of cationic substrates, but not for proton 
translocation (Adler and Bibi, 2004).  Most of the other implicated amino acids are either 
hydrophobic or slightly hydrophobic and are likely involved in the binding of zwitterionic 
lipophilic substrates. 
MdfA is an excellent candidate for structural and biochemical studies because of its 
relatively small size and its substrate specificity.  The protein has a large substrate range, yet 
it is specific enough not to transport normal constituents out of the cell.  Fully understanding 
the substrate binding site of this protein would be extremely interesting and the knowledge 
acquired could be applied to other multidrug transporters, potentially aiding in the treatment 
of multidrug resistant cancers, epilepsy, AIDS and bacterial infections which have become 
multidrug resistant due to the over-expression of multidrug transporters. 
 
 
Figure 2.11.  Stereo view of the superposition of three substrates in the QacR binding site 
(Murray et al., 2004) (PDB ID 1RPW).  The substrates are pentamidine (yellow), hexamidine 
(green) and dequalinium (red). 
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2.4 Protein Structural Studies  
 Protein structural studies are a very important part of biochemistry.  The elucidation of 
protein structures can yield detailed information about how proteins and enzymes function.  
There are two main methods for solving three-dimensional protein structures: X-ray 
crystallography and NMR.  X-ray crystallography is the most common method used for 
structural studies and has produced the most structures.  On March 10, 2009 there were 
56,217 structures deposited in the Protein Data Bank (PDB), and of those structures 48,162 
were X-ray crystal structures, 7,729 were NMR structures, and 221 were cryo-electron 
microscopy structures.  
2.4.1. X-ray Crystallography 
Protein crystals of high quality are required for solving a high-resolution protein 
structure by X-ray crystallography.  Protein crystals are made up of regularly repeating units 
of identical shape and size called unit cells.  Protein crystals are formed by slowly 
supersaturating a purified protein sample, forcing the protein out of the liquid phase and into 
the solid phase as a highly-ordered crystal.  The most common method for obtaining a 
supersaturated protein solution is by adding a precipitant which leads to a change in water 
content.   A protein crystal is then placed into an X-ray beam, where the electrons from the 
atoms in the crystal lattice diffract the incident X-ray beam.  An electron density map can be 
then generated from the observed X-ray diffraction pattern.  Phase angles cannot be directly 
recorded during diffraction.  Prior to generating an electron density map, the phase angles 
must be determined using one of three methods: multiple isomorphous replacement, 
multiwavelength anomalous dispersion, or molecular replacement.  Once the electron density 
map is obtained, the protein model must be fit into the electron density map and refined.  
 There are several benefits to X-ray crystallography.  A major advantage of X-ray 
crystallography is that there is no protein size limitation.  Proteins of all sizes have been 
crystallized and their structures solved.  The structure for the complete 70S ribosome was 
solved by X-ray crystallography to the resolution of 2.8 Ångstroms (Selmer et al., 2006).  The 
70S ribosome is about 2.5 MDa in size and is made up of three large RNA molecules and 
over 50 small proteins.  The largest advantage to X-ray crystallography is the ability to obtain 
extremely high resolution structures.  At the resolution of 5.5 Ångstrom, the overall shape of 
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the molecule can be determined.  At 3.5 Ångstrom resolution, the main chain of the protein 
can be observed.  At 3 Ångstrom resolution, the side chains can be partially resolved.  At 1.5 
Ångstrom resolution, the amino acid side-chains can be completely resolved and the atoms in 
the structure will be located to about +/- 0.1 Ångstrom accuracy.  The best resolution obtained 
using X-ray crystallography is 0.54 Ångstroms for the protein Crambin (Jelsch et al., 2000).  
Membrane proteins generally have poorer resolution compared to soluble protein.  However, 
X-ray structures for membrane proteins have been solved to an extremely high resolution.  
The structure of Aqy1 yeast aquaporin was solved to 1.15 Ångstrom resolution (Fisher et al., 
2009). 
X-ray crystallography also has its drawbacks.  The biggest drawback to X-ray 
crystallography is the need to obtain suitable protein crystals.  The process of protein 
crystallization can be very difficult and time consuming.  This is especially true for membrane 
proteins.  Membrane proteins are relatively hydrophobic and need to be solubilized in order to 
be extracted from the lipid bilayer.  Solubilization can be achieved using detergents.  
Detergents interact with hydrophobic surfaces on the protein, forming micelles around them 
which allows for their extraction from the lipid bilayer.  The presence of detergents greatly 
hampers crystallization attempts.  Detergent micelles conceal many potential crystal contacts, 
which are required for the formation and growth of crystals.  The few remaining contacts can 
result in crystal formation, but the protein crystals are generally delicate and fragile.  The 
micelle that surrounds the protein generally has a flexible and dynamic nature which also 
interferes with crystal formation.  The magnitude of this problem is reflected in the statistics 
for crystallized proteins. In the PDB, there are over 48,000 protein crystal structures, and of 
those structures, only approximately 200 are of unique membrane proteins 
(http://blanco.biomol.uci.edu/ Membrane_Proteins_xtal.html, June 24/2009). 
A second disadvantage of X-ray crystallography is encountered with substrate binding 
studies.  The substrate either needs to be soaked into the crystal or co-crystallized with the 
protein, which can also result in crystallization difficulties.  If the protein has multiple 
substrates, this opens up the possibility of multiple crystal forms and multiple crystallization 
conditions which makes crystallization trials time consuming.   
Another drawback to X-ray crystallography is that the chemical composition of the 
crystallization liquor can potentially lead to conformational changes, resulting in a non-
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physiological protein structure.  Crystal formation itself may select one of several protein 
conformations present in the solution, or force the protein into a region of conformational 
space, sparsely populated under physiological conditions.  X-ray structures give static models, 
whereas proteins are dynamic.  Crystallization restricts the protein’s movements and may 
result in a physiologically irrelevant structure.  Mobile or disordered regions of the protein 
will not be seen in X-ray crystallography, and may hinder crystallization attempts.  That being 
said, most X-ray structures provide physiologically relevant information.  The structures of 
many proteins have been solved using both X-ray crystallography and NMR.  Garbuzynskiy 
and co-authors compared the X-ray and NMR structures for some 60 proteins.  In most cases, 
the X-ray and NMR structures of the same protein had only small differences, possibly due to 
packing restrictions in crystals (Garbuzynskiy et al., 2005).  The pairwise RMSDs of the 
backbone atoms were calculated comparing the X-ray structures to the NMR structures of the 
60 different proteins (Garbuzynskiy et al., 2005).  The RMSD values for 42 of the 60 proteins 
were under 2.00, including 0.52 for ubiquitin, 0.57 for interleukin-1 beta, and 0.83 for human 
cyclophilin A.  There were only five proteins with RMSD values higher than 3, the highest 
being 3.99.  These low RMSD values indicate that there was no significant difference 
between the X-ray and NMR structures for most proteins.  Despite the drawbacks to X-ray 
crystallography, it is still the most powerful method of protein structural analysis.   
2.4.2. Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance spectroscopy can also be used to solve protein 
structures. Chemically distinct protons, carbon atoms and nitrogen atoms in the protein can be 
identified through the measurement of the chemical shifts of their respective nuclei.  The 
interatomic distances can be then estimated by measuring Nuclear Overhauser effect, 
magnetization transfer through space, which makes protein structure elucidation by NMR 
possible.  Measuring magnetization transfer through space allows the computation of 
distances between protons, and thus the distances between structural elements.  The 
compilation of multiple distance constraints within the protein can then be used to produce a 
three-dimensional protein model.   
Uniform isotope labeling allows for the collection of information on the entire protein.  
Isotope labeling is necessary in protein NMR because naturally-occurring isotopes of carbon 
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and nitrogen are not useful for high resolution NMR studies.  
12
C has no magnetic moment 
and therefore is not NMR-active, while the high nuclear quadrupole moment of 
14
N prevents 
obtaining high resolution spectra.  Nuclei with spin number of ½, such as 
13
C and 
15
N, have 
the most favorable properties for high resolution NMR.  Therefore, uniform isotope labeling 
of proteins using 
13
C and 
15
N isotopes allows for high resolution NMR studies of proteins.  
However, when investigating specific portions of a protein molecule, such as using chemical 
shift perturbation experiments to map a drug binding site, the use of uniform isotope labeling 
would result in a very complicated spectrum wherein the chemical shifts would be difficult to 
observe.  Such experiments are made easier by using selective isotope labeling.  By labeling 
only amino acids believed to be involved in the binding of substrates, the resulting NMR 
spectrum is greatly simplified.  Through selective isotope labeling, it is possible to map active 
sites of protein without having to solve the entire structure.  By labeling only the amino acids 
thought to be involved in substrate binding, the intermolecular distances can be calculated and 
a three-dimensional map of the active site can be generated.   
The range of proteins that can be effectively studied by high-resolution NMR is 
limited by molecule size restrictions.  The larger the protein, the faster the relaxation of the 
NMR signals.  Fast relaxation results in broad NMR spectral lines, which in turn leads to loss 
of resolution and sensitivity. Additional difficulties arise in the NMR studies of membrane 
proteins, such as the choice of detergent, which can play a very important role in the NMR 
experiment.  The detergent will form a micelle around the protein, adding to the overall size 
of the molecule.  It is important to choose a detergent that will result in the smallest micellar 
size, yet still maintain the proper folding of the protein being studied.   
Several methods have been developed to deal with large proteins in NMR studies.  
One method is deuteration of the protein.  Deuteration improves NMR spectra for large 
proteins by reducing the dipolar interactions between 
13
C or 
15
N and the directly bound proton 
spins, which is the main source of relaxation in 
13
C- and 
15
N-labeled proteins (Browne et al., 
1973; Grzesiek et al., 1993), significantly increasing relaxation time.  The most significant 
method developed to address the problem of magnetization relaxation of large proteins is 
transverse relaxation optimized spectroscopy (TROSY) (Pervushin, et al., 1998).  The 
TROSY experiment results in the spectral peaks appearing as multiplets because decoupling 
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has not been applied.  TROSY is designed to then select only the narrow spectral component 
of N-H multiplets, resulting in narrower line widths, and dramatically higher resolution.   
An advantage of NMR is that proteins are studied in solution, which avoids the 
difficulties of protein crystallization.  Unlike crystal structures, NMR protein structures are 
not static.  Structures solved by NMR contain information on the conformational flexibility of 
the protein.  Additional NMR techniques can be used to obtain detailed information on 
protein dynamics.  Heteronuclear Nuclear Overhauser effects and relaxation rates provide 
direct information on the range and timescale of local molecular motions.  The extent of 
conformational flexibility can be calculated as an order parameter using the Lipari-Szabo 
model free approach (Lipari and Szabo, 1982).  This in combination with Nuclear Overhauser 
effects and residual dipolar coupling measurements (Bouvignies et al., 2007) can be used to 
describe molecular motions fairly accurately.   
Another advantage of NMR is the ability to determine what amino acids are involved 
in substrate binding by using chemical shift perturbation analysis.  Chemical shifts are 
sensitive to changes in the local environment.  Chemical shifts for those amino acids involved 
in substrate binding will experience perturbations upon the addition of substrate to the protein 
solution.  These chemical shift perturbations can be observed by comparing NMR spectra 
from a protein sample with and without substrate added.  Interpretation of such experiments 
may be complicated by the fact that chemical shift perturbations will also be observed for an 
amino acid residue located in the region, which experience significant structural changes 
because of substrate binding.   
The structures of several membrane proteins have been solved using NMR 
experiments.  Two examples are KcsA and diacylglycerol kinase.  KcsA is a potassium 
channel which was extracted from the membrane using the detergent foscholine.  NMR 
studies revealed that KcsA exhibits a tetrameric arrangement of helical KcsA monomers 
(Figure 2.12).  The NMR structure obtained for KcsA is consistent with the previously 
determined X-ray structure (Yu et al., 2005).  Unlike KcsA, the structure determined for 
diacylglycerol kinase is unique, as there is no X-ray structure available.  The NMR structure 
of diacylglycerol kinase solubilized in dodecylphosphocholine revealed a homotrimer with 
interlinking helices (Figure 2.13) (Van Horn et al., 2009).     
21 
 
 
Figure 2.12.  Side view of the ribbon representation of KcsA (Yu et al., 2005) (PDB ID 
2A9H).  Two monomers are colored green and two monomers are colored grey.  Reprinted 
with permission from the American Chemical Society.   
 
Figure 2.13.  Diacylglycerol kinase structure ensemble comprised of the 16 lowest energy 
structures (Van Horn et al., 2009) (PDB ID 2KDC).  Reprinted with permission from AAAS.
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2.5. Overview of Protein Preparation for Structural Studies. 
In order to conduct protein structural studies using X-ray crystallography or NMR, it is 
important to obtain pure protein.  In order to obtain pure protein, one must choose a suitable 
expression system.  Generally, it is preferable to produce the protein in the correctly folded 
conformation and not within inclusion bodies.  Once an appropriate expression plasmid is 
chosen with a compatible bacterial host, the correctly folded, over-expressed protein must then 
be purified from the bacterial cells.  This is done by rupturing the bacteria and then using 
protein fractionation methods to remove contaminants and isolate the protein of interest.  If the 
protein is not expressed in a soluble form, it may be necessary to use detergents to solubilize 
the protein prior to purification.   
Initial screening of crystallization conditions in X-ray crystallographic studies typically 
requires 1 mL solution at a protein concentration of 10 mg/mL and at 95% purity or higher.  
Protein NMR spectroscopy typically requires a sample between 300-600 L in volume with a 
protein concentration of 0.1 mM- 3.0 mM.  It is also extremely important that the pure protein 
is stable.  Many structural studies require proteins to be stable for weeks or months in a range of 
temperatures and experimental conditions.  Protein stability can be affected by many 
parameters, including pH, salt concentration, presence of inhibitors and cofactors, residual 
protease activity and detergents employed in the study.   
Another important characteristic of the protein in structural studies is its aggregation 
state.  It is vital that the protein is present in solution in a monodisperse, though not necessarily 
monomeric state.  Dimers, trimers and aggregates of higher order can be analyzed by X-ray 
crystallography and NMR, as long as the protein is present as a single species.  A non-uniform 
aggregation state of a protein solution can inhibit the formation of high resolution crystals in X-
ray crystallography.  Protein aggregation in NMR will lead to very broad spectral lines resulting 
in peak overlap, signal disappearance and an overall poor NMR spectrum.  The aggregation 
state of a protein in solution can be analyzed using dynamic light scattering experiments.  
Dynamic light scattering is a technique in which a beam of monochromatic light is directed 
through a purified protein solution and the fluctuations of intensity of scattered light is 
analyzed.  This information can be used to determine the particle size distribution of the 
solution, and thus the aggregation state of the protein in solution.  The aggregation state of the 
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protein can be affected by several different factors, including protein concentration, salt 
concentration and detergent concentration.   
2.5.1. Cloning the Gene of Interest into an Expression Vector 
Expression plasmids are commonly constructed to encode at least one antibiotic 
resistance gene for selection, an inducible promoter, and a purification tag that can be linked to 
the protein to be expressed.  Some examples are the pET vectors (EMD Biosciences, San 
Diego, California), the pTYB vectors (New England BioLabs, Pickering, Ontario), and the 
pBAD vectors (Invitrogen, Burlington, Ontario).  The pBAD vector features an ampicillin 
resistance gene for selection, a thioredoxin gene for possible purification of a fusion protein, a 
V5 epitope for antibody detection, and an (L)-arabinose inducible promoter.  The isopropyl -
D-1-thiogalactopyranoside inducible promoter, found in the pET and pTYB vectors, is the most 
commonly used inducible promoter.  The pBAD plasmid with the (L)-arabinose inducible 
promoter was chosen for this study because it offers tight control of expression, the inducing 
agent is relatively inexpensive, and MdfA has been successfully expressed previously using a 
similar system (Lewinson and Bibi, 2001).  As well, some other membrane proteins such as 
GlpT and the MexA, B-OprM extrusion pump have also been successfully expressed using this 
system (Guan et al., 1999; Huang et al., 2003). 
The arabinose promoter offers extremely tight control of gene expression.  The pBAD 
plasmid also encodes the araC gene.  AraC both positively and negatively regulates 
transcription based on arabinose and cyclic AMP (cAMP) concentrations (Ogden et al., 1980; 
Schleif, 1992).  AraC functions as a dimer, and in the absence of arabinose it binds the O2 and 
I1 sites in the plasmid (Figure 2.14), creating a DNA loop which inhibits transcription.  In the 
presence of arabinose, the dimer will release the O2 site and bind to the I2 site, which releases 
the DNA loop and allows transcription to begin.  The cAMP activator protein (CAP) binds to 
DNA in the presence of cAMP further promoting AraC binding to I2.  Upon the addition of 
glucose, cAMP levels are lowered, resulting in reduced binding of CAP, which leads to the 
decrease of transcriptional activation.  Arabinose concentrations in the cytoplasm, and therefore 
gene expression level, can be easily adjusted by using a strain which is unable to metabolize 
(L)-arabinose.  Being able to tightly regulate gene expression may be necessary if the protein is 
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toxic to the bacteria or if high concentrations of the protein results in the aggregation and 
precipitation of the protein.   
Another option for protein expression is to use a cell-free expression system such as the 
one described by Torizawa and co-authors (Torizawa et al., 2004).  Cell-free synthesis exploits 
the cellular protein synthesis machinery to direct protein synthesis outside intact cells using 
exogenous messenger RNA or DNA as a template (Figure 2.15).  This is achieved by 
combining a crude lysate from growing cells, containing necessary enzymes and machinery for 
protein synthesis, with an exogenous supply of amino acids, nucleotides, salts and energy-
generating factors.  Since the protein synthesis is done in vitro, and not in a bacterial cell, this 
method allows production of toxic proteins.  The pEXP-DEST (Invitrogen, On, Canada) cell- 
 
Figure 2.14.  The action of the AraC dimer in promoting (bottom) or inhibiting (top) protein 
expression from the pBAD expression plasmid. (pBAD Directional TOPO Expression Kits 
instruction manual (Invitrogen, On, Canada)). 
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free synthesis plasmid includes a T7 RNA polymerase promoter to ensure selective gene 
expression from this plasmid using T7 RNA polymerase. Once an expression system is 
selected, the cDNA encoding the protein is sub-cloned into the plasmid.  This can be 
accomplished by modifying the gene sequence encoding the protein to be flanked by restriction 
sites chosen for cloning into the specific vector.  The restriction sites can be inserted at the 5
’
 
and 3
’
 ends of the gene of interest through polymerase chain reaction with DNA primers 
encoding the restriction sites.  Once the matching restriction sites are added, both the gene and 
the vector can be digested with the restriction enzymes, ligated together and the ensuing 
product is then transformed into the bacterial host.  Constructs are screened via restriction 
analysis and then verified by DNA sequencing.  An alternate option is to use homologous DNA 
recombination methods. 
 
 
Figure 2.15.  The principle of cell-free synthesis (Schwarz et al., 2007).  A crude lysate from 
growing cells containing the necessary enzymes and machinery for protein synthesis is 
combined with exogenous supply of amino acids, nucleotides, salts and energy-generating 
factors.  ARSases: aminoacyl-tRNA synthetases.  Detergents can be added to aid in protein 
folding and solubility.  Reprinted with permission from Elsevier. 
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2.5.2. Optimization of Protein Production. 
There are many ways to increase protein expression.  One method is to test expression 
of the gene of interest in different bacterial strains.  For example, BL21 (DE3) derivatives such 
as C43 (DE3) and C41 (DE3) were designed for the over-expression of toxic proteins as well as 
membrane proteins (Miroux and Walker, 1996).  Varying the inducing agent concentration can 
also result in higher levels of protein expression.  However, it is important that the expressed 
protein is properly folding.  If too much protein is being expressed too quickly, the protein may 
not fold correctly, which can result in aggregation leading to formation of the inclusion bodies.  
Therefore, optimal inducing agent concentration may not be that which results in the highest 
level of expression.  Increasing incubation time can also result in higher expression levels.   
2.5.3. Producing Isotopically Labeled Protein samples. 
NMR experiments may require uniformly or selectively isotopically labeled protein 
samples.  There are several ways to accomplish such a labeling.  For uniformly labeled protein 
samples, it is common to express the protein in bacteria growing on a minimal medium 
containing the source of the required isotope for incorporation into the amino acids during their 
biosynthesis in the bacterial cell.  An example would be to use a growth medium where the 
only nitrogen source is 
15
N ammonium chloride, which would result in the uniform labeling of 
the backbone amide groups of the protein with 
15
N, as well as Asn, Gln, Arg, Trp, His, and Lys 
side chains.  A similar approach can be used to obtain selectively labeled protein samples by 
using a medium supplemented with isotopically labeled amino acids.  This, however, requires a 
large amount of labeled amino acids and can lead to improper labeling and isotope dilution as a 
result of metabolic scrambling.  Metabolic scrambling occurs when one amino acid is converted 
into another through metabolic pathways in the bacterial cell.  Metabolic scrambling can be 
overcome by using auxotrophic strains of bacteria for protein expression, or by using cell-free 
protein synthesis.  Auxotrophic strains of bacteria contain mutations which render them unable 
to synthesize specific amino acids.  These amino acids can be added externally in a labeled 
form and will be incorporated into the newly synthesized proteins largely avoiding metabolic 
scrambling.  There is also no metabolic scrambling in cell-free protein synthesis because the 
amino acid metabolic activity in cell-free extracts is low (Kigawa et al., 1995).  The amount of 
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isotopically labeled amino acids needed for cell-free synthesis is much lower, because only the 
protein of interest is produced.  
2.5.4. Purification of Cell Membranes 
 When purifying membrane proteins, it is necessary to separate the cell membrane from 
soluble cytosolic protein, as well as other cell debris.  Once the cell culture has been pelleted 
using centrifugation, the cells can be disrupted using a method such as French press or 
sonication, then the cell membranes can be separated from cytosolic proteins through a series of 
centrifugation steps.  The first centrifugation is usually carried out at speeds resulting in the 
force of around 6000 x g, separating the membranes and soluble protein from other cell debris, 
including inclusion bodies.  Ultracentrifugation at around 100,000 x g is then used to separate 
the soluble cytosolic proteins from the membranes, as the membranes will pellet out of 
solution.  The cell membranes are collected and used for protein purification.  
2.5.5. Protein Extraction from the Cell Membrane 
Membrane proteins need to be extracted from the cell membrane in order to be purified.  
This is accomplished by adding a detergent which will interact with the hydrophobic surfaces 
of the protein, thereby allowing the protein solubilization.  Detergents are amphipathic 
molecules comprising a polar head group and a non-polar hydrocarbon tail.  Detergents used for 
solubilization must maintain both the structural integrity and biological activity of the protein of 
interest.   Membrane solubilization trials are performed using a wide range of detergents at 
concentrations higher than their critical micelle concentrations (CMC).  The CMC is a 
minimum concentration where detergent monomers aggregate, forming micelles into which 
membrane proteins can be inserted.  Membrane proteins have been purified in a wide range of 
detergents.  Some detergents which have been used to solubilize membrane proteins include: 3-
[3-(Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) (Banerjee et al., 1995; 
Cladera et al., 1997; Chattopadhyay, et al., 2002), n-dodecyl--D-maltoside (DDM) 
(Ambramson et al., 2003; Yin et al., 2006), sodium cholate (Rivnay and Metzger, 1982) and 
Triton X-100 (Aller et al., 2009).  Several membrane transporters of MFS type, including 
LacY, EmrD, EmrE, GlpT and MdfA have been successfully solubilized using DDM (Auer et 
al., 2001; Ambramson et al., 2003; Adler, et al., 2004; Yin et al., 2006; Korkhov and Tate, 
2009).  When conducting NMR experiments on the solubilized protein, the detergent must not 
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interfere with the quality of the NMR spectra.  Krueger-Koplin and co-authors (Krueger-Koplin 
et al., 2004) evaluated the quality of NMR spectra of subunit c of the E. coli F1Fo ATP 
synthase, subunit c from B. pseudofirmus OF4, Smr from S. aureus, and LH1 and  subunits 
from R. sphaeroides,  recorded in different detergents.  Of these detergents, CHAPS, DDM and 
Triton resulted in poor quality NMR spectra, while detergents such as 1-myristoyl-2-hydroxy-
sn-glycero-3-[phospho-rac-1-(glycerol)] (LMPG) and 2-Diheptanoyl-sn-Glycero-3-
Phosphocholine (DHPC) resulted in NMR spectra of high quality.  The structures of the 
detergents discussed can be seen in figure 2.16 and are listed in table 2.1. 
 
 
       
 
       
 
  
 
 
Figure 2.16.  Chemical structures of detergents commonly used to solubilize membrane 
proteins. 
 
 
a) 3-[3-(Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) 
b) octylglucoside (OG) 
c) n-dodecyl--D-maltoside (DDM) d) Triton X-100 
e) 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-1-(glycerol)] (LMPG) 
g) Sodium Cholate f) 2-Diheptanoyl-sn-Glycero-3-Phosphocholine 
(DHPC) 
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Table 2.1. A list of detergents commonly used to solubilize membrane proteins. 
Figure 
2.16 
Detergent Name CMC Common 
Abbreviation 
a) 3-[3-
(Cholamidopropyl)dimethylammonio]-
1-propanesulfonate 
6-10 mM CHAPS 
b) octylglucoside 19 mM OG 
c) n-dodecyl--D-maltoside 0.17 mM DDM 
d) Triton X-100 0.23 mM na 
e) 1-myristoyl-2-hydroxy-sn-glycero-3-
[phospho-rac-1-(glycerol)] 
0.05 mM LMPG 
f) 2-Diheptanoyl-sn-Glycero-3-
Phosphocholine 
1.4 mM DHPC 
g) 3 ,7 ,12 -Trihydroxy-5β-cholan-24-oic acid, 
monosodium salt 
9-14 mM Sodium Cholate 
 
 
2.5.6. Protein Purification 
 There are several different protein purification methods, including size exclusion 
chromatography, ion-exchange chromatography, and affinity chromatography.  Size exclusion 
chromatography separates proteins based on their molecular size and shape.  A gel matrix of 
porous beads is used for the immobile phase in the column chromatography.  Smaller proteins 
follow a longer trajectory through the pores, whereas larger proteins are unable to enter the 
smaller pores, which effectively leads to separation based on molecule size and shape.  Ion-
exchange chromatography separates proteins based on charge.  The chromatography matrix can 
either be positively charged (anion-exchange) binding negatively charged proteins, or be 
negatively charged (cation-exchange) binding positively charged proteins.  The bound proteins 
can then be serially eluted by gradually increasing the salt concentration in the solvent.  
Affinity chromatography is a chromatographic method for separating proteins based on highly 
specific interactions, such as those between antigen and antibody, or receptor and ligand.  
Affinity chromatography methods commonly used for purification of recombinant proteins 
generally involve modification of the protein sequence by adding a specific amino acid 
sequence, called a tag, which has an affinity for the immobile phase of the chromatography 
column.  The elution step will vary based on what affinity chromatographic method is used.    
At present, affinity chromatography is the most common method of purifying proteins.  
Some examples of tags used are Glutathione S-transferase (GST) which binds glutathione resin 
30 
 
(Smith and Johnson, 1988), poly-histidine patches which bind divalent metals (Hochuli et al., 
1987), maltose binding protein which binds amylase resin (Bedouelle et al., 1987), and intein-
chitin binding domain (CBD), which binds chitin (Chong et al., 1997).  In GST affinity 
chromatography, the vector has been modified so the fusion protein can be cleaved from GST 
by digestion with the site specific protease thrombin (Smith and Johnson, 1988).  Poly-
histidine-tagged proteins can be eluted from their interaction with divalent metals, such as 
nickel ions chelated by nitrilotriacetate groups, by washing the column with imidazole which 
out-competes histidine for the divalent metal.  Maltose-binding protein-tagged proteins are 
eluted off amylase resin by washing it with maltose (Bedouelle, et al., 1987).  Intein-CBD-
tagged proteins are eluted from immobilized chitin by incubating with a reducing agent such as 
1, 4-dithiothreitol which reduces the disulfide bond connecting the protein to the tag (Chong et 
al., 1997).  These affinity purification methods often offer efficient one-step purification, 
resulting in pure protein.   
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3. Materials and Methods
1
 
3.1. Plasmids and Strains 
3.1.1. Generation of a Plasmid for Cell-Based Protein Expression 
Plasmids were purified from the E. coli cell culture using a Miniprep kit (Qiagen, 
Mississauga, Ontario). The mdfA gene and its native ribosome-binding site were cloned into a 
pBAD102 vector (Invitrogen) under the control of an araBAD promoter (Dmitriev, unpublished 
data).  The native ribosome-binding site is located immediately upstream of the mdfA gene.  In 
the resulting plasmid pOD1016, the mdfA gene was fused to the V5 epitope sequence for 
immunodetection and a C-terminal hexa-histidine tag for purification (Figure 3.1 A).  The 
plasmid also contained the thioredoxin gene, which was present in the pBAD102 vector for 
purification of fusion proteins, but was out of frame with mdfA and therefore was not used in 
our procedure.  The pOD1016 plasmid was further modified to delete the sequences encoding 
for thioredoxin and the V5 epitope.  The V5 epitope was deleted because it was not needed, 
since MdfA was successfully detected using anti-penta-histidine antibody.  The gene encoding 
thioredoxin was deleted to determine if its absence would result in higher levels of mdfA 
expression.  This new construct was named pCOG3 (Figure 3.1 B).  To construct the pCOG3 
plasmid, PCR was carried out using the pOD1016 vector as a template, with primers designed 
to create a NcoI cleavage site at the 5’ end (MFM1NCO, Table 3.1), and to delete the V5 
epitope sequence (MRM2061, Table 3.1) at the 3’ end  of the mdfA gene.  The resulting 1.3 kb 
product (Figure 3.2, lane 2) was digested with the restriction endonuclease NcoI.  The 
pOD1016 vector was digested with the restriction endonucleases NcoI and PmeI, resulting in 
1.7 Kb and 4.0 kb fragments (Figure 3.2, lane 4).  The digested PCR product was ligated to the 
NcoI-PmeI fragment of the pOD1016 vector, transformed into DH5 cells, and selected with 
ampicillin.  Plasmid identity was confirmed by restriction digest with NcoI, which produced 
one fragment with the expected size of 5.3 kb (Figure 3.2., lane 6) and by DNA sequencing 
using the primer MRS146 (Table 3.1).  Plasmids with the correct sequence were transformed 
into LMG194 cells (Invitrogen). 
                                                 
1
 Chemicals used in these experiments were purchased from Sigma-Aldrich (Oakville, Ontario) unless otherwise 
stated. 
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Figure 3.1. The pOD1016 vector (A) and pCOG3 vector (B).  The pOD1016 vector has the 
mdfA gene fused to a V5 epitope and the sequence encoding a hexa-histidine tail.  A 
thioredoxin tag and enterokinase (EK) recognition site are present upstream of mdfA for use in 
purification, but are out of frame with mdfA, and not used in purification.  MdfA was cloned 
directly into the linearized pBAD vector using blunt-end PCR product and a proprietary process 
called “directional TOPO cloning” (pBAD Directional TOPO Expression Kits instruction 
manual (Invitrogen)).  In the pCOG3 vector, the mdfA gene is fused to the sequence encoding a 
hexahistidine tag.  Included in both vectors are the pBAD promoter, the araC gene encoding 
the regulatory protein for the pBAD promoter, and a pUC origin allowing high-copy replication 
and maintenance in E. coli.  PmeI and/or NcoI cleavage sites are labeled. 
 
 
Table 3.1. A list of primers used in generating pCOG2 and pCOG3. 
Primer Name Sequence (5’-3’) 
MFM1NCO GAAATTCCATGGAAAATAAATTAGCTTCCGGTGCCAGG 
MRM2061 TCAATGGTGATGGTGATGATGCCCTTCGTGAGAATTTC 
MRS146 ATCAATGCCCGCCTGATATTG 
MFM1NDE TTGCATATGCAAAATAAATTAGCTTCCGGTGCCAGGCTTG 
MRM1233 TGCTAGCTCAATGGTGATGGTGATGATGCCCTTCGTGAG 
PDEST1F GACTCACTATAGGGAGACCAC 
PDEST1R TGTTAGCAGCCGGATCAAGC 
 
 
 
MdfA 
MdfA 
pOD1016 pCOG3 
A B 
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Figure 3.2. Generation of pCOG3.  DNA fragments were separated on a 1% agarose gel and 
stained with ethidium bromide   Lanes 1, 3, and 5: DNA standards; lane 2:  PCR product 
containing the mdfA gene; lane 4: pOD1016 plasmid digested with the restriction enzymes 
PmeI and NcoI; lane 6: pCOG3 digested with the restriction enzyme NcoI. 
 
3.1.2. Generation of a Plasmid for Cell-Free Synthesis  
The mdfA gene was also cloned into the plasmid pEXP1-DEST (Invitrogen) for cell-free 
synthesis.  This new construct was named pCOG2 (Figure 3.3).  To construct the pCOG2 
plasmid, PCR was carried out using the pOD1016 vector as a template, with primers designed 
to create both an NdeI cleavage site at the 5’ end (MFM1NDE, Table 3.1) and an NheI cleavage 
site at the 3’ end (MRM1233, Table 3.1).  The resulting 1.3 kb product (Figure 3.4, lane 2) was 
digested with the restriction endonucleases NheI and NdeI.  The pEXP1-DEST vector was also 
digested with the endonucleases NheI and NdeI, resulting in a 4.6 kb fragment (Figure 3.4, lane 
4).  The digested PCR product was ligated to the NheI-NdeI fragment of the pEXP1-DEST 
vector, transformed into DH5 cells, and selected with ampicillin.  Plasmid identity was 
confirmed by a restriction digest with NheI and NdeI, which produced two fragments with the 
expected sizes of 1.3 kb and 4.6 kb (Figure 3.4, lane 6), and also by DNA sequencing using the 
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primers PDEST1F and PDEST1R (Table 3.1).  Plasmids with the correct identity were 
transformed into One-shot ccdB survival T1 phage-resistant cells (Invitrogen).  
 
 
Figure 3.3. The pCOG2 plasmid.  This plasmid contains a T7 promoter for specific expression 
by T7 RNA polymerase, a ribosome binding site, the ccdB gene for negative selection of the 
plasmid, a T7 transcription termination sequence, f1 origin to allow for the rescue of single-
stranded DNA, and the pUC origin to permit high-copy replication and maintenance in E. coli. 
 
 
 
 
MdfA 
pCOG2 
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Figure 3.4.  Generation of pCOG2.  DNA fragments were separated on a 1% agarose gel and 
stained with ethidium bromide.  Lanes 1, 3 and 5: DNA standards; lane 2: PCR product 
containing the mdfA gene; lane 4: pEXP1-DEST plasmid digested with the restriction enzymes 
NheI and NdeI; lane 6: pCOG2 digested with the restriction enzyme NheI and NdeI. 
 
3.1.3. Bacterial Strains used in the Cloning and Expression of mdfA 
E. coli strains used in this research include C43 (DE3), DH5, LMG194, and One-shot 
ccdB survival T1 phage-resistant cells.  The C43 (DE3) cells metabolize arabinose, and have at 
least one uncharacterized mutation, which prevents the cell death associated with the expression 
of toxic recombinant proteins (Miroux and Walker, 1996).  The C43 (DE3) cells have the 
genotype F
-
ompT gal hsdSB (rB
-
mB
-
) dcm lon DE3.  The DH5 cells are able to take up large 
plasmids (nupG) and have the genotype F
- 
endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG 80dlacZM15 (lacZYA-argF)U169, hskR17(rK
-
 mK
+
), -.  LMG194 cells cannot 
metabolize arabinose (ara714) and have the genotype F- lacX74 galE thi rpsL phoA (Pvu 
II) ara714 leu::Tn10.  The One-shot ccdB survival cells are resistant to the ccdB gene product 
and have the genotype F
-
 mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 
ara139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::152. 
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3.2. Optimization of mdfA Expression 
MdfA expression in E. coli cells was optimized by varying the concentration of the 
inducer agent (L)-arabinose present in the growth medium.  MdfA expression from the plasmids 
pOD1016 and pCOG3 in the strains LMG194 and C43 (DE3) was investigated.  Expression 
was induced in Luria Broth (LB) containing 170 mM NaCl, 10 g/L tryptone, and 5 g/L yeast 
extract; casamino acid medium (RM) containing 2% casamino acids, 0.5% glycerol, 1 mM 
MgCl2, 42 mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl, and 20 mM NH4Cl; or M63 minimal 
medium containing 15 mM NH4Cl, 15 mM Na2SO4, 1 mM MgSO4, 0.5% glycerol, 15 M 
thiamine, 2 mM leucine, 100 mM potassium phosphate buffer, pH 7.0.  Cell cultures were 
grown at 37
o
C on a shaker platform at 200 r.p.m. to an optical density (OD600) of 0.4, and then 
(L)-arabinose was added to a final concentration of 0.0002% - 2.0%.  The cultures were 
incubated for an additional 4 hours under the same conditions.  Culture samples were then 
taken and diluted to an equal optical density (OD600).  The 1 mL aliquots of each sample were 
then pelleted and resuspended in a lysis buffer containing 50 mM potassium phosphate, pH 7.8, 
400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% Triton X-100, and 10 mM imidazole, and 
then disrupted in a sonication bath for 5 minutes.  Samples were then centrifuged at 18,000 x g 
for 1 minute.  The resulting pellets and supernatants were analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) using 10% polyacrylamide gels (Schagger 
and von Jagow, 1987), transferred to a nitrocellulose membrane by blotting at 0.4 Amp for 90 
minutes, and probed by Western blot analysis (Towbin et al., 1979) using a monoclonal 
antibody against penta-histidine epitope (Qiagen).  
 MdfA was also expressed in a cell-free system from the pCOG2 plasmid using the 
method previously described by Torizawa and co-authors (Torizawa et al., 2004).  The cell-free 
protein synthesis reactions were carried out in 100 L samples, with or without the presence of 
100 g liposomes, containing from 2 to 8 g of the pCOG2 plasmid.  Expression was 
performed at 37
o
C for 120 minutes.  MdfA expression levels were analyzed by SDS-PAGE 
followed by Western blot analysis.   
3.3. Gel Electrophoresis of Protein 
All SDS-PAGE was carried out using 10% polyacrylamide gels with or without the 
addition of 6 M urea (Schagger and von Jagow, 1987).  Western blot analysis was carried out as 
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explained by Towbin and co-authors (Towbin et al., 1979).  Protein samples were transferred 
from 10% polyacrylamide gels to nitrocellulose membrane by blotting at 0.4 Amp for 90 
minutes.  The nitrocellulose membrane was blocked using blocking reagent (Qiagen), and 
detection was accomplished using an anti-penta-histidine-HRP-conjugate antibody (1:10000 
dilution).  Chemo luminescence was achieved through incubation with 100 mM Tris, pH 8.5 
containing 1.25 mM luminol, 0.225 mM d-cumaric acid, and 0.01% hydrogen peroxide. 
3.4. Preparation of Cell Membranes for MdfA Extraction. 
LMG194 cells containing the pCOG3 plasmid were grown in LB at 37
o
C on a shaker 
platform at 200 r.p.m. to an optical density (OD600) of 0.4. (L)-arabinose was added to a final 
concentration of 0.002% and the cultures were incubated for an additional 4 hours.  The cells 
were then pelleted by means of centrifugation (6,000 x g for 15 minutes at 4
o
C).  The cells were 
lysed via French press at 18,000 p.s.i. in a buffer containing 50 mM Tris-HCl, pH 7.5, 5 mM 
MgCl2 1 mM dithiothreitol, 10% glycerol (v/v) and 1 mM phenylmethylsulfonyl fluoride 
(TMDG buffer).  Cell debris was removed by centrifugation (7,700 x g for 15 minutes) and 
then the membranes were purified by centrifugation of the low-speed supernatant at 100,000 x 
g for 75 minutes.  The pellet was then resuspended in TMDG buffer and centrifuged under the 
same conditions.  The membrane pellet was resuspended once more in TMDG buffer and 
frozen in liquid nitrogen. 
3.5. MdfA Detergent Extraction from Cell Membranes 
 MdfA extraction from the membrane was attempted using the following five detergents: 
Triton X100 (BioRad, Mississauga, Ontario), octylglucoside (Fisher BioReagents, Ottawa, 
Ontario), DHPC (Avanti, Alabaster, Alabama), DDM and LMPG (Avanti) at concentrations 
ranging from 0.5% to 2.0% (w/v).  The membrane samples were diluted to 10 mg protein /mL 
with TMDG buffer, mixed with the detergent at the appropriate final concentration and 
sonicated in a bath sonicator for 5 minutes.  Samples were then ultracentrifuged (220,000 x g 
for 20 minutes) to separate soluble and insoluble protein.  The soluble and insoluble fractions 
were analyzed by SDS-PAGE, followed by Western blot analysis. 
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3.6. MdfA Purification 
MdfA was extracted from the cell membrane using DHPC at a final concentration of 
2.0%.  Membrane samples were diluted to a protein concentration of 10 mg/mL and incubated 
with detergent, followed by gentle agitation for 30 minutes at 4
o
C.  Samples were 
ultracentrifuged (100,000 x g for 60 minutes) to pellet the insoluble fraction.  The soluble 
fraction was loaded onto a column containing nickel nitrilotriacetic acid agarose (Ni-NTA 
agarose) (Qiagen).  The column was washed with TMDG buffer containing 0.4% DHPC and 20 
mM imidazole to remove contaminating proteins.  MdfA was eluted in a TMDG buffer 
containing 0.4% DHPC and 250 mM imidazole.  Purification through extraction with DDM 
was performed using the same procedure, except that DDM was substituted for DHPC.   
For NMR sample preparation, MdfA was transferred into LMPG micelles.  Briefly, 
MdfA was extracted from the membrane and loaded onto a Ni-NTA column as described 
above. The column was washed with TMDG containing 0.4% DHPC and 20 mM imidazole and 
then with TMDG containing 0.2% LMPG and 20 mM imidazole, effectively replacing DHPC 
micelles with LMPG micelles.  MdfA was eluted with TMDG containing 0.2% LMPG and 250 
mM imidazole.  Due to the high cost of LMPG, it was not used in the extraction procedure.   
3.7. Isotopic Labeling of MdfA for NMR Studies 
 In order to isotopically label MdfA, LMG194 cells containing the pCOG3 plasmid were 
grown on LB at 37
o
C on a shaker platform at 200 r.p.m. to an optical density (OD600) of 0.4 
then pelleted by centrifugation (6,000 x g for 15 minutes at 4
o
C).  Cells were resuspended in 
M63, RM, or E. coli OD2 medium (Silantes, München Germany), supplemented with 
isotopically labeled compounds as described in detail below.  (L)-arabinose was added to a final 
concentration of 0.002% and cultures were incubated for an additional 4 hours.  A 
15
N- labeled 
MdfA sample was generated by inducing mdfA expression in M63 medium containing 15 mM 
15
N ammonium chloride (Cambridge Isotope Labs, Andover, Massachusetts) as the sole source 
of nitrogen.  A 
13
C, 
15
N, 
2
H- labeled MdfA sample was generated inducing mdfA expression in 
M63 medium formulated with 100% deuterium oxide (Cambridge Isotope Labs), containing 15 
mM 
15
N ammonium chloride as the sole source of nitrogen and 0.5% (v/v) 
13
C glycerol 
(Cambridge Isotope Labs) as the sole source of carbon.  A 
13
C-Glu, 
15
N-Phe-labeled MdfA 
sample was generated by inducing mdfA expression in M63 medium supplemented with 0.25 
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mM 
13
C Glu and 0.25 mM 
15
N Phe.  Fluoro-tryptophan labeled MdfA was generated by 
expressing mdfA in RM medium supplemented with 1 mM 5-fluoro-tryptophan.  A 
13
C, 
15
N-
double-labeled MdfA sample was made by expressing mdfA in E.coli OD2 
13
C, 
15
N-labeled 
medium.  MdfA was extracted with DHPC and purified as described above into LMPG 
micelles.  
3.8. Dynamic Light Scattering 
Dynamic light scattering experiments were conducted at the Saskatchewan Structural 
Sciences Center (SSSC) using the DynaPro/Micro Sampler with Dynamics Software package 
(Dynamics ™ version 5.26.60).  Dynamic light scattering was performed on MdfA purified 
using DHPC, DDM, and LMPG at protein concentrations ranging from 2 mg/mL to 7 mg/mL. 
3.9. MdfA Stability Optimization 
The stability of purified MdfA was assessed by measuring the percentage of total 
protein that remained soluble after incubation at 27
o
C for periods of up to 72 hours.  Stability of 
MdfA was tested in a 25 mM sodium phosphate buffer containing 0.4% DHPC or 0.2% LMPG, 
at pH 5, 6, 7 or 8, with or without 100 mM NaCl.  Buffer exchange was achieved by diluting 
1:10 purified MdfA in an appropriate buffer and concentrating it to the starting volume, using 
an Amicon Ultra protein concentrator (Millipore, Billerica, Massachusetts) with a 10,000 Da 
molecular weight cutoff.  This procedure was repeated three times.  After buffer exchange, 
samples were incubated at 27
o
C for 0, 48, or 72 hours.  At those times, aliquots were taken, 
pelleted in a desktop centrifuge at 18,000 x g for 3 minutes, and the protein concentration of the 
supernatant was determined using the Lowry protein assay (Lowry et al., 1951).   
3.10. Nuclear Magnetic Resonance Experiments 
 NMR spectroscopy on 
15
N-, 
15
N, 
13
C, 
2
H-, 
15
N, 
13
C- and 
13
C-Glu, 
15
N-Phe- labeled 
MdfA were performed by Dr. Oleg Dmitriev either at the SSSC using a 600 MHz Bruker 
spectrometer equipped with a Cryoprobe, or at the National Magnetic Resonance Facility in 
Madison, Wisconsin (NMRFAM) on a 750 MHz Bruker spectrometer with a Cryoprobe.  
19
F 
NMR experiments were conducted at the SSSC on a 500 MHz Bruker spectrometer equipped 
with a 
1
H, 
19
F-probe at 315K. The samples contained between 0.133-0.266 mM protein, 25 mM 
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sodium phosphate buffer, pH 6.0, 5% (v/v) D2O, 0.2% LMPG, 50 mM NaCl, and 0.5 mM 2,2-
dimethyl-2-silapentane-5-sulfonic acid for chemical shift referencing.   
3.11. Reconstitution of MdfA into Proteoliposomes  
 Liposomes were prepared from an E. coli total lipid extract in chloroform (Avanti).  The 
organic solvent was evaporated to dryness under a gentle stream of argon, and the lipid was 
resuspended in a solution containing 100 mM potassium phosphate, pH 7.0, 2 mM -
mercaptoethanol, and 1.5% octylglucoside to a final lipid concentration of 25 mg/mL.  
Liposomes were dialyzed against 100 mM potassium phosphate, pH 7.0 and 2 mM -
mercaptoethanol using a 12,000-14,000 Da molecular weight cutoff SpectraPor dialysis tubing 
(Spectrum Laboratories Inc., Rancho Domingeuz, California).   
Preformed liposomes were passed through a mini-extruder (Avanti Polar Lipids) using a 
Whatman polycarbonate membrane (Ge Healthcare, Piscataway, New Jersey) with a 100 nm 
pore size to ensure uniform size distribution.  Liposomes were resuspended in a 300 L 
solution containing 100 mM potassium phosphate at pH 7.0, 2 mM -mercaptoethanol, and 2% 
Triton-X 100 at 12.5 mg/mL lipid concentration, mixed with 60 g of purified MdfA and 
incubated at 30
o
C for 15 minutes.  Detergents were removed by incubating liposomes at 30
o
C 
with several changes of Bio-beads (BioRad) for a total time of 150 minutes, using a total of 120 
mg Bio-beads per 300 μL liposome suspension.  Bio-beads were pre-treated as follows: 10 g of 
Bio-beads were added to 70 mL methanol and gently stirred for 15 minutes.  The beads were 
washed with 700 mL ddH2O and then transferred to a vacuum flask and degassed for 6 hours, 
changing the ddH2O every 2 hours.   
3.12. MdfA Activity Assay by ACMA Fluorescence  
MdfA is an H
+
/Drug antiporter, and therefore drug transport can be indirectly monitored 
by measuring the H
+
 transport coupled to drug translocation.  A transport assay using the 
fluorophore 9-amino-6-chloro-2-methoxyacridine (ACMA) as a reporter of H
+
 transport has 
been developed.  The assay principle is illustrated in Figure 3.5.  Liposomes were loaded with 
K
+
, while the assay buffer contained Na
+
.  Valinomycin was added to the assay solution, 
allowing K
+
 to diffuse down its concentration gradient out of the liposome, creating an electric 
potential difference across the membrane (positive outside.  Addition of carbonyl cyanide 
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4-(trifluoromethoxy)-phenylhydrazone (FCCP) allowed flow of protons down the 
electrochemical gradient into the liposome, lowering its internal pH.  ACMA can pass freely 
through the lipid bilayer in the electroneutral form, but not in the positively charged protonated 
form.  ACMA added to the solution became protonated upon entering the liposome and 
accumulated inside, causing concentration-dependent fluorescence quenching.  Addition of an 
MdfA substrate, such as ethidium bromide, to the solution resulted in the pumping of the 
substrate into the liposome in exchange for H
+
, increasing internal pH, which in turn increased 
concentration of the deprotonated ACMA inside the liposome. The uncharged form of ACMA 
diffused out of the liposome, diluting in the external medium, which resulted in the increase of 
the ACMA fluorescence.   
 
 
 
Figure 3.5.  The principle of the fluorescence assay of MdfA activity.  The addition of 
valinomycin and FCCP allow for the diffusion out of K
+
 and the influx of H
+
 down the 
electrochemical gradient (The lowering of liposomal pH results in the sequestering of 
ACMA, causing concentration-dependent fluorescence quenching.  Ethidium bromide (EtBr) is 
added and is pumped into the liposome in exchange for H
+
, allowing ACMA to leave the 
liposome, and increasing fluorescence intensity. 
Valinomycin 
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The MdfA activity assay detected by ACMA fluorescence was carried out in a 10 mM 
Tricine buffer at pH 7.0, containing 5 mM magnesium sulfate and 200 mM sodium sulfate.  
Fluorescence excitation was set to 410 nm and emission at 490 nm.  ACMA was added to a 
final concentration of 1 M.  A total of 250 g of proteoliposomes by lipid content was added 
to the 2 mL assay solution followed by addition of valinomycin to a final concentration of 
0.0125 M.  To achieve ACMA quenching, FCCP was added to a final concentration of 0.025 
M.  Either chloramphenicol, or ethidium bromide was added to final concentrations ranging 
from 0.25 M to 25 M and ACMA fluorescence recovery was monitored. 
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4. Results 
4.1. MdfA Expression Optimization 
4.1.1. Comparison of mdfA Expression Levels from pOD1016 and pCOG3 Plasmids at 
different Arabinose Concentration. 
In order to generate a large enough quantity of MdfA protein suitable for structural 
studies, the level of mdfA expression had to be optimized. We tested mdfA expression in the 
pBAD102 vector, which offers tight control of expression using (L)-arabinose to induce 
expression and glucose to inhibit background expression prior to induction.  The gene encoding 
MdfA was previously cloned into the pBAD102 vector yielding pOD1016 plasmid (Dmitriev, 
unpublished data).  The pCOG3 plasmid was generated from the pOD1016 plasmid by deleting 
the genes encoding thioredoxin and the V5 epitope.  The thioredoxin gene was deleted to 
determine if the absence of its expression would affect mdfA expression.  The V5 epitope was 
deleted because a commercially-available anti-penta-histidine antibody effectively detected the 
hexa-histidine tag fused to MdfA for purification purposes.  We compared mdfA expression 
from the plasmids pOD1016 and pCOG3 in LMG194 strain under identical conditions (Figure 
4.1).  There was no significant difference in mdfA over-expression between the pCOG3 and 
pOD1016 plasmids (Figure 4.1).  Deletion of the thioredoxin gene did not result in higher mdfA 
expression.  Additional bands seen in Figure 4.1 are likely MdfA aggregates as discussed in 
detail below.  Maximum mdfA expression levels were achieved upon the addition of (L)-
arabinose to the final concentration of 0.0002 %. 
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             LMG194/pOD1016                         LMG194/pCOG3 
 
Figure 4.1.  MdfA expressed from LMG194/pOD1016 and LMG194/pCOG3 cells in a range of 
(L)-arabinose concentrations.  SDS-PAGE and subsequent Western blot analysis was 
performed as described under “Materials and Methods”.  All cell samples were diluted to OD600 
of 0.7.  The 1 mL fractions were then sonicated and centrifuged as described under “Materials 
and Methods”.  The pelleted material was resuspended in 1 mL sample buffer, and 20 L of the 
pellet samples were loaded into the corresponding lanes.  Subunit a of ATP synthase containing 
a hexa-histidine tag was used as a control.   The concentrations of (L)-arabinose used for 
induction are listed below their corresponding lanes.   
 
4.1.2. Comparison of mdfA Expression Levels in the LMG 194 and C43 (DE3) Cells 
The pCOG3 plasmid was also transformed into C43 (DE3) cells to determine if 
expression levels of mdfA would increase when compared to LMG194.  C43 (DE) cells are 
effective in expressing toxic and membrane proteins (Miroux and Walker, 1996).  C43 (DE3) 
cells metabolize (L)-arabinose, and as such, were expected to require more (L)-arabinose to 
induce expression compared to a non-(L)-arabinose metabolizing strain such as LMG194.  
Indeed, maximum mdfA expression in C43 (DE3) strain was achieved at (L)-arabinose 
concentrations of 0.02% and above (Left at panel, Figure 4.2). There was no significant 
difference in maximum mdfA expression levels between the strains C43 (DE3) and LMG194 
(Figure 4.2).  LMG194/pCOG3 cells were subsequently used for mdfA expression for 
purification purposes because of the smaller requirement of (L)-arabinose.  Due to inconsistent 
expression at 0.0002% (L)-arabinose, further mdfA expression for purification purposes was 
performed using 0.002% (L)-arabinose.   
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                     C43 (DE3)/pCOG3                        LMG194/pCOG3 
 
Figure 4.2.  MdfA expressed from C43 (DE3)/pCOG3 and LMG194/pCOG3 cells in a range of 
(L)-arabinose concentrations.  SDS-PAGE and subsequent Western blot analysis was 
performed as described under “Materials and Methods”.  All cell samples were diluted to OD600 
of 0.7.  The 1 mL fractions were then sonicated and centrifuged as described under “Materials 
and Methods”.  The pelleted material was resuspended in 1 mL sample buffer, and 20 L of the 
pellet samples were loaded into the corresponding lanes.  Subunit a of ATP synthase containing 
a hexa-histidine tag was used as a control.   The concentrations of (L)-arabinose used for 
induction are listed below their corresponding lanes.  Lanes 1 and 6: molecular weight 
standards.   
 
4.1.3. Determination of Optimal mdfA Expression Levels on Different Media 
 Prior to commencing preliminary NMR experiments, it was necessary to determine if 
mdfA could successfully be expressed in a minimal medium.  Gene expression in minimal 
medium allows for simple uniform isotope labeling as well as selective amino acid isotope 
labeling of the protein.   
MdfA expression levels were tested in several different growth media.  First, 
LMG194/pCOG3 cells were grown to mid-logarithmic phase in the LB medium. The cells were 
pelleted, resuspended and induced in either LB, M63 minimal medium, or, RM.  After four 
hours of induction, the cells were pelleted and the level of mdfA expression was then examined 
by Western blot analysis (Figure 4.3).  Visual inspection of Figure 4.3 indicates mdfA was 
expressed slightly higher in RM or M63 minimal medium than in LB.  Similar or higher levels 
of mdfA expression in RM and M63 minimal medium made it possible for the generation of 
both selective and uniform isotope-labeled MdfA samples using these media. 
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Figure 4.3.  MdfA expressed by LMG194/pCOG3 in LB, RM, and M63 minimal medium.  
SDS-PAGE and subsequent Western blot analysis was performed as described under “Materials 
and Methods”.  All cell samples were diluted to OD600 of 0.7.  The 1 mL fractions were then 
sonicated and centrifuged as described under “Materials and Methods”.  The pelleted material 
was resuspended in 1 mL sample buffer, and 20 L of the pellet samples were loaded into the 
corresponding lanes.   
 
4.1.4. MdfA Synthesis in a Cell-free System  
 Amino acid selective isotopic labeling can significantly facilitate NMR of large 
proteins.  We have tested the feasibility of using cell-free synthesis for amino acid selective 
isotopic labeling of MdfA for NMR studies.  
 For cell-free protein expression of mdfA, the gene encoding MdfA was cloned into the 
pEXP-DEST vector, generating the plasmid pCOG2.  This plasmid features a T7 promoter, 
which is essential to prevent transcription of the endogenous DNA present in the cell extract 
used for cell-free synthesis.  Only genes under the control of T7 promoter will be expressed 
using T7 RNA polymerase added to the reaction mixture.  MdfA was synthesized using pCOG2 
in a cell-free synthesis system and analyzed by Western blot as shown in Figure 4.4.  The 
amount of expressed mdfA (Figure 4.4, lane 3), was similar to the amount of subunit a of E. coli 
ATP synthase expressed under identical conditions.  The yield of subunit a in the cell-free 
synthesis system was about 0.1 mg/mL reaction mixture (Dmitriev and Uhlemann, 2007), 
which is sufficient to make sample preparation for NMR practical.  MdfA was also expressed in 
the presence of liposomes to promote proper folding (Figure 4.4, lane 5).  Liposomes were 
prepared as described under section 2.10.  The prepared liposomes were passed through a mini-
extruder (Avanti Polar Lipids) using a Whatman polycarbonate membrane (Ge Healthcare) with 
a 100 nm pore size to ensure uniform size distribution prior to use.  However, experiments to 
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determine if MdfA was incorporated into the liposomes were inconclusive and further 
investigation is needed (data not shown). 
4.2. Membrane Incorporation of MdfA 
Overproduction of a membrane protein can lead to three possible outcomes.  The 
protein can be degraded upon production, it can be inserted into the membrane, or it can form 
inclusion bodies in the cytoplasm.  It was important that MdfA be inserted into the membrane, 
because proteins which form inclusion bodies are commonly improperly folded.  To determine 
distribution of over-produced MdfA in the subcellular fractions, a cell culture induced with 
0.002% (L)-arabinose was pelleted, passed through French Press to disrupt the cells and 
centrifuged at a low speed.  Low speed centrifugation pelleted much of the cell debris, 
including inclusion bodies, whereas cellular membranes remained in the supernatant.  Most of 
the MdfA was indeed found in the membrane-containing fraction of the induced cells (Figure 
4.5, lane 4), and only minute quantities of MdfA were detected in the low speed pellet (Figure 
4.5, lane 3).  Membranes were purified through ultracentrifugation and subsequently used for 
MdfA extraction. 
 
 
                  
Figure 4.4.  MdfA synthesized in the cell-free synthesis system.  SDS-PAGE and subsequent 
Western blot analysis was performed as described under “Materials and Methods”.  5 L of the 
cell-free synthesis solution was loaded in each lane.  Lane 1: molecular weight standard; lane 2: 
cell-free synthesized subunit a from ATP synthase; lane 3: cell-free synthesized MdfA; Lane 4: 
cell-free synthesis solution lacking expression plasmid; lane 5: cell-free synthesized MdfA in 
the presence of 100 g liposomes; lane 6: 10 L membrane preparation containing MdfA. 
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Figure 4.5.  Distribution of MdfA between the subcellular fractions.  SDS-PAGE and 
subsequent Western blot analysis was performed as described under “Materials and Methods”.  
The pellet sample was resuspended in a volume equal to that of the supernatant and then 10 L 
of each sample were loaded into each lane.  Lane 1: molecular weight standard; lane 2: crude 
cell extract; lane 3: pellet after centrifugation of the crude cell extract at 7700 x g; lane 4: 
supernatant after centrifugation of the crude cell extract at 7700 x g. 
  
4.3. Detergent Extraction of MdfA from Cell Membranes 
 Several detergents, including Triton-X 100, octylglucoside, DHPC, DDM, and LMPG, 
were tested for MdfA extraction from the lipid bilayer.  The detergents were added to 
membrane samples containing MdfA.  Soluble protein was separated from insoluble material by 
ultracentrifugation.  The effectiveness of MdfA extraction by each detergent was evaluated by 
comparing the quantity of MdfA present in the soluble fractions with the amount in the 
insoluble fractions.  While Triton-X 100 did not solubilize MdfA to any significant extent 
(Figure 4.6, Triton-X 100), octylglucoside achieved maximum MdfA solublization at a 
concentration of 2.0% (Figure 4.6, Octylglucoside).  DHPC was also found to achieve 
maximum MdfA solublization at a concentration of 2.0% (Figure 4.6, DHPC) while LMPG 
reached maximum MdfA solublization at 0.5% (Figure 4.6, LMPG).  Lastly, DDM achieved 
maximum solublization at a concentration of 1.0% (Figure 4.6, DDM).  Both LMPG and DDM 
appear to be the most effective at extracting MdfA from the cell membrane (Figure 4.6). 
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Figure 4.6.  The extraction of MdfA from membrane samples using the detergents Triton-X 
100, octylglucoside, DHPC, LMPG, and DDM.  SDS-PAGE and subsequent Western blot 
analysis was performed as described under “Materials and Methods”.  Each sample, containing 
10 mg/mL protein in a volume of 250 L was centrifuged to separate the soluble and insoluble 
fractions.  The insoluble fraction was resuspended in 250 L TMDG and 10 L of either the 
soluble (S) or insoluble (I) fractions were loaded into each lane.  The first lane in each picture 
contains molecular weight standards.  The final concentrations of the detergents used are listed 
below their corresponding lanes. 
 
4.4. Optimization of MdfA Purification. 
 In order to determine if MdfA can be purified from the LMPG extract of the cell 
membrane by means of its C-terminal hexa-histidine tag, we tested binding of the protein to Ni-
NTA agarose followed by elution with imidazole (Figure 4.7).  MdfA bound to Ni-NTA 
agarose and was eluted with 100 mM imidazole.  Comparison of samples loaded on the column 
(Figure 4.7, lane 10) with fractions eluted with imidazole (Figure 4.7, lane 7) shows the 
majority of MdfA loaded onto the column was recovered after elution.  No bound MdfA was 
detected on the Ni-NTA beads after elution (Figure 4.7, lane 8), indicating that MdfA could 
potentially be purified via its hexa-histidine tag.   
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Figure 4.7.  Ni-NTA chromatography of MdfA in the presence of 1% LMPG SDS-PAGE and 
subsequent Western blot analysis was performed as described under “Materials and Methods”.  
10 L from each fraction was loaded on the gel.  Lane 1: molecular weight standard; lanes 2-6: 
column wash samples; lane 7: the eluted fraction; lane 8: bead sample after elution; lane 9: 
subunit a from ATP synthase; lane 10: soluble fraction of the membrane extract loaded onto the 
column.   
 
 LMPG is an ideal detergent for NMR experiments (Krueger-Koplin et al., 2004), but it 
is expensive.  We attempted to purify MdfA using DHPC as an alternative to LMPG.  When 
DHPC was used in the purification of MdfA, results similar to the LMPG purification were 
obtained (Figure 4.8).  
 
 
   
Figure 4.8.  Ni-NTA chromatography of MdfA in the presence of 2% DHPC.  SDS-PAGE and 
subsequent Western blot analysis was performed as described under “Materials and Methods”.  
10 L of each fraction was loaded into its corresponding lanes.  Lane 1: molecular weight 
standard; lanes 2-3: column wash; lane 4: bead sample prior to elution; lane 5: the eluted 
fraction.  
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Following pilot experiments, a large scale purification of MdfA was performed.  MdfA 
was first purified using solely DHPC detergent, but the purification procedure was subsequently 
modified to include a detergent exchange stage, replacing DHPC with LMPG.  MdfA was 
extracted from the membrane fraction with DHPC as described under Materials and Methods.  
Detergent extract was loaded onto a Ni-NTA column and washed with buffer containing 0.4% 
DHPC and 20 mM imidazole to remove non-specifically bound protein (Figure 4.9, lane 5).  
MdfA binding to Ni-NTA beads was visualized by comparing the crude membrane extract 
loaded on the column with the column flow-through (Figure 4.9, lanes 3 and 4).  The MdfA 
band was present in the former, but was absent in the latter (circled region in Figure 4.9, lanes 3 
and lanes 4).  Thus MdfA remains bound to the column. To improve elution of non-specifically 
bound protein and to exchange detergent, a second wash was performed with a buffer 
containing 0.2% LMPG and 20 mM imidazole (Figure 4.9, lane 6).  MdfA was eluted using a 
buffer containing 0.2% LMPG and 250 mM imidazole (Figure 4.9, lanes 7-10).  Large scale 
purification in this manner yielded an average of 1.0 - 1.4 mg of MdfA per 1 L culture as 
determined using Lowry protein assay (Lowry et al., 1951).  MdfA was also successfully 
purified using the detergent DDM (Figure 4.10).   
 
 
Figure 4.9.  Coomassie stained 10% polyacrylamide gel showing the purification of DHPC-
extracted MdfA by means of Ni-NTA chromatography.    10 L of each sample was loaded on 
the gel.  Lane 1: molecular weight standard; lane 2: cell membranes (10 mg/mL protein); lane 
3: DHPC extract loaded onto the column; lane 4: flow-through during column loading; lane 5: 
20 mM imidazole wash containing 0.4% DHPC; lane 6: 20 mM imidazole wash containing 
0.2% LMPG; lanes 7-10: purified MdfA samples eluted by 250 mM imidazole.  Bands 
corresponding to MdfA monomer are shown by the arrow.  The area containing monomeric 
MdfA band in the DHPC extract (lane 3) and column flow-through (lane 4) is circled. 
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Figure 4.10.  Coomassie stained 10% polyacryalmide gel of MdfA purified in DDM detergent 
micelles.  Lane 1: molecular weight standards; lane 2: 4 g purified MdfA; lane 3: 10 g 
purified MdfA. 
 
 4.5. Aggregation Propensity of MdfA.  
In addition to monomeric MdfA, MdfA purified by Ni-NTA chromatography contained 
several diffuse bands at higher molecular weights as revealed by SDS-PAGE, followed by 
either Coomassie staining or silver staining (Figure 4.11).  These bands were detectable via 
Western blot analysis with anti-penta-histidine antibody used to detect MdfA (Figure 4.11).  
The molecular weights of the corresponding proteins were determined based on band migration 
distances using molecular weight standards for calibration.  Molecular weights corresponding 
to the four bands detected by Western blot (Figure 4.11 B) were determined to be 28 kDa, 57 
kDa, 87 kDa, and 111 kDa (Figure 4.12).  These values are consistent with the molecular 
weights of MdfA monomer, dimer, trimer, and tetramer respectively.  MdfA is 47 kDa in size, 
but it was found to migrate at around 30 kDa during SDS-PAGE.  It is not unusual for the 
molecular weight of a membrane protein to be underestimated from SDS-PAGE migration 
distance (Miyake et al., 1978; Rath et al., 2009).  Membrane proteins can bind more SDS per 
unit weight due to their extreme hydrophobicity and therefore have a larger negative charge and 
migrate farther through the SDS-PAGE gel than hydrophilic proteins of the same size.  
Previous studies have also found that MdfA migrates at an apparent molecular weight of around 
30 kDa via SDS-PAGE (Lewinson and Bibi, 2001).   
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Figure 4.11.  Silver-stained gel (A) and Western blot analysis (B) of purified MdfA.  SDS-
PAGE and subsequent Western blot analysis was performed as described under “Materials and 
Methods”.  Lane 1: 0.2 g MdfA; Lane 2: 2 g MdfA; Lane 3: 5 g MdfA.  The arrows point 
to the bands corresponding to MdfA and its oligomers. 
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Figure 4.12.  The molecular weight determination of MdfA oligomers.  Migration distance of 
the protein standards is plotted as a function of the logarithm of molecular weight ().  
Migration distance of the MdfA aggregates is shown by the arrows. 
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Prior to the realization that the additional bands observed in SDS-PAGE gels were 
likely MdfA aggregates, all SDS samples were treated at the standard 100
o
C for 3 minutes.  
Since membrane protein aggregation in SDS is often temperature-dependent, I investigated the 
effects of temperature treatment of MdfA SDS samples on band intensity in SDS-PAGE.  
Strong temperature dependence of the band intensity was observed and provided further 
evidence that the additional bands correspond to MdfA oligomers (Figure 4.13).  Pure MdfA 
was divided into four aliquots, which were either incubated at 37
o
C, 75
o
C, 100
o
C, or autoclaved 
prior to analysis via SDS-PAGE.  An intense band corresponding to MdfA monomer was 
observed in the sample treated at 37
o
C (Figure 4.13, panel A and B, row 4).  The relative 
intensity of additional bands corresponding to MdfA oligomers increased dramatically when the 
sample was treated at higher temperatures.  If the additional bands corresponded to proteins 
other than MdfA, varying the temperature should not have significantly affected the resolution 
pattern seen in the SDS-PAGE gels.  Since the additional bands are MdfA oligomers, the 
purified MdfA samples are in fact pure, and contain very little contaminating protein. 
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Figure 4.13.  Silver-stained gel (A) and Western blot analysis (B) of purified MdfA samples 
incubated at different temperatures prior to SDS-PAGE.  Samples were loaded onto a 10% 
SDS-PAGE gel containing 6 M urea.  Western blot analysis was performed as described under 
“Materials and Methods”.  Lanes 1-4: 2 g MdfA.  Temperature treatments are shown above 
the lane.  
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4.6. Analysis of MdfA Aggregation State by Dynamic Light Scattering 
The yield of 1.0 - 1.4 mg pure MdfA per 1 L culture was sufficient to initiate 
crystallization trials.  Monodisperse protein samples are generally required for successful 
crystallization.  Dynamic light scattering experiments showed that the purified MdfA was 
monodisperse in DHPC (Figure 4.14), DDM (Figure 4.15), and LMPG detergent micelles 
(Figure 4.16) up to 4 mg/mL protein concentration and at a range of temperatures up to 30
o
C.  
Nearly all the particles present in the solution were found to be around 3-4 nm in size, which is 
around the size expected for a globular protein of 50 kDa (Dynamics Software package, version 
5.26.60).  MdfA however, is not a globular protein, but a 3-4 nm diameter is a reasonable 
estimate for MdfA in a detergent micelle. 
 
 
 
Figure 4.14.  Dynamic Light Scattering analysis on MdfA.  A purified MdfA sample at a 
protein concentration of 4 mg/mL in 0.4% DHPC was tested at 25
o
C using the DynaPro/Micro 
sampler at the SSSC.   
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Figure 4.15.   Dynamic Light Scattering analysis on MdfA.  A purified MdfA sample at a 
protein concentration of 4 mg/mL in 0.4% DDM was tested at 25
o
C using the DynaPro/Micro 
sampler at the SSSC. 
 
 
Figure 4.16.  Dynamic Light Scattering analysis on MdfA.  A purified MdfA sample at a 
protein concentration of 4 mg/mL in 0.2% LMPG was tested at 25
o
C using the DynaPro/Micro 
sampler at the SSSC. 
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4.7. MdfA Stability Optimization 
In order to conduct crystallization trials or NMR experiments on MdfA, it was 
necessary to ensure that MdfA was stable for long periods of time as crystallization trials and 
NMR experiments can last for several weeks, or even several months.  Initially, MdfA in 
solution was only stable for two days at 27
o
C.  In an attempt to increase the stability of MdfA in 
solution, different buffer conditions were investigated (see Materials and Methods for details).  
MdfA stability was measured in DHPC and LMPG detergent micelles, at pH 5, 6, 7, and 8, and 
in the presence or absence of 100 mM NaCl (Figure 4.17).  MdfA was most stable in LMPG 
detergent micelles at pH 5-6 in the presence of 100 mM NaCl.  Under these conditions, nearly 
100% of the protein remained soluble after 72 hours at 27
o
C.  Further visual observation 
revealed that it remained soluble for several more days at 27
o
C and for two months at room 
temperature. 
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Figure 4.17.  Stability of the purified MdfA protein in a 25 mM sodium phosphate buffer 
containing either 0.2% LMPG or 0.4% DHPC, at pH 5-8, with or without 100 mM sodium 
chloride.    
 
4.8. Preliminary MdfA Crystallization Trials  
 An MdfA sample purified in LMPG detergent micelles was sent to the High-
Throughput Crystallization Lab at the Hauptman-Woodward Institute for Crystal Screening.  
The screens resulted in several conditions (Table 4.1) that yielded possible protein crystals 
(Figure 4.18).  Unfortunately, upon reproduction of the conditions, the crystals that were found 
were not made up of protein.  Further screening was conducted using the MPD Suite (Qiagen), 
which resulted in two sets of conditions that formed crystals (Figure 4.19).  Initial testing by 
Ponceau S staining indicates that these crystals may be protein and experiments to grow larger 
crystals are underway.  
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Table 4.1.  List of crystallization conditions from the high-throughput crystallization screens 
which were chosen for reproduction and further investigation. 
 
Crystal Screen Composition 
0.05 M CsCl2, 0.1 M MES monohydrate pH 6.5, 30% (v/v) Jeffamine M-600 
3.82 M MnCl2, 0.1 M sodium citrate, pH 4.2 
2.13 M (NH4)2HPO4, 0.1 M HEPES, pH 7.5 
3.73 M LiBr, 0.1 M Bis-Tris Propane, pH 7 
1.59 M MgSO4*7H2O, 0.1 M TAPS, pH 9 
0.39 Zn(C2H3O2)2, 0.1 M sodium acetate, pH 5 
0.1 M NH4NO3 0.1 M TAPS, pH 9, 20% (w/v) PEG 20000 
0.1 M Zn(C2H3O2)2, 0.1 M sodium acetate, pH 5, 20% (w/v) PEG 20000 
0.1 M LiBr, 0.1 M CAPS, pH 10, 40% (w/v) PEG 20000 
0.1 M Mg(C2H3O2)2*4H2O, 0.1 M TAPS, pH 9, 40% (w/v) PEG 20000 
0.1 M K2HPO4, 0.1 M Bis-Tris Propane, pH 7, 20% (w/v) PEG 8000 
0.1 M K2HPO4, 0.1 M Tris, pH 8, 20% (w/v) PEG 8000 
0.1 M Mg(NO3) 2*6H2O, 0.1 M TAPS, pH 9, 20% (w/v) PEG 8000 
0.1 M LiCl, 0.1 M Tris pH 8, 20% (w/v) PEG 4000 
0.1 M MgSO4*7H2O, 0.1 M TAPS, pH 9, 20% (w/v) PEG 4000 
0.1 M MnCl2, 0.1 M Bis-Tris Propane pH 7, 20% (w/v) PEG 4000 
0.1 M MgCl2*6H2O, 0.1 M TAPS, pH 9, 20% (w/v) PEG 1000 
0.1 M MnCl2, 0.1 M sodium acetate, pH 5, 20% (w/v) PEG 1000 
0.1 M Mg(C2H3O2)2*4H2O, 0.1 M sodium acetate, pH 5, 40% (w/v) PEG 400 
0.1 M MgSO4*7H20, 0.1 M MES, pH 6, 40% (w/v) PEG 400 
0.1 M Zn(C2H3O2)2, 0.1 M sodium acetate, pH 5, 40% (w/v) PEG 400 
0.1 M Ca(C2H3O2)2, 0.1 M sodium acetate, pH 5, 20% (w/v) PEG 400 
0.8 M Lithium sulfate monohydrate, 0.1 M Tris, pH 8.5 
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Figure 4.18.  Examples of crystallization conditions chosen from the high-throughput 
crystallization trials for further investigation.  (A) A sample containing 0.05 M CsCl2, 0.1 M 
MES monohydrate pH 6.5 and 30% (v/v) Jeffamine M-600; (B) sample containing 3.82 M 
MnCl2 and 0.1 M sodium citrate, pH 4.2. 
 
 
 
 
Figure 4.19.  Photographs of Ponceau S stainable crystals found in MdfA crystal screens.  (A) 
A sample containing 40% 2-methyl-2,4-pentanediol, and 0.2 M CaCl2; (B) sample containing 
40%  2-methyl-2,4-pentanediol and 0.2 M ammonium nitrate.  Photographs courtesy of Carla 
Protsko. 
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4.9. Preliminary MdfA Nuclear Magnetic Resonance Experiments 
After stability optimization, several MdfA samples with different isotope labeling 
patterns were generated for NMR studies.  The samples included uniform 
15
N-labeled, uniform 
13
C, 
15
N, 
2
H-labeled, 
13
C-Glu, 
15
N-Phe-labeled, and 5-fluoro-tryptophan-labeled proteins.  
15
N- 
and 
13
C, 
15
N, 
2
H-labeling can be used to solve the three-dimensional protein structures.  
13
C-
Glu, 
15
N-Phe-labeling and 5-fluoro-tryptophan-labeling can be used in substrate binding 
studies.  It may also be possible to use 5-fluoro-tryptophan-labeling for NMR sample 
optimization.   
4.9.1. Substrate Binding to MdfA Measured by 
19
F NMR 
19
F NMR chemical shift perturbation experiments were carried out to determine if they 
could be used to detect whether purified MdfA binds its substrates or not.  5-fluoro-tryptophan 
labeling was chosen as reporter groups because the substrate binding site of MdfA is believed 
to be hydrophobic and the 10 hydrophobic tryptophan residue are evenly spaced throughout the 
transmembrane region of the MdfA sequence, where it is likely that some of the tryptophan 
residues will be located in the substrate binding site and will register substrate binding in the 
chemical shift perturbation assays.  Since there are 10 tryptophan residues in MdfA, the 
19
F 
NMR spectrum of a 5-fluoro-tryptophan-labeled MdfA sample should therefore consist of ten 
peaks.  MdfA labeled with 5-fluoro-tryptophan (Figure 4.20) resulted in a spectrum exhibiting 
several overlapping wide peaks (Fig 4.21).  The overlapping peaks and wide spectral lines are 
probably due to fast relaxation of magnetization of the protein during the NMR experiment.  
The peaks in the 
19
F NMR spectra that have a signal-to-noise ratio greater than two were very 
reproducible, being observed in all successful 
19
F NMR experiments.  Upon addition of 
ethidium bromide, a substrate of MdfA, minor spectral changes were observed, suggesting that 
MdfA bound ethidium bromide (Figure 4.22).   
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Figure 4.20.  The structure of 5-fluoro-tryptophan.  The fluorine is encircled. 
 
 
 
 
Figure 4.21.  One-dimensional NMR spectrum of 5-fluoro-tryptophan-labeled MdfA (Top) and 
the one-dimensional NMR spectrum of the buffer solution (Bottom). 
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Figure 4.22.  One dimensional NMR spectrum of 5-fluoro-tryptophan-labeled MdfA titrated 
with EtBr.  The EtBr concentrations in the NMR samples are labeled beside the corresponding 
spectra.  The vertical red line is added for reference. 
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The 
19
F NMR experiment was repeated using another MdfA substrate, chloramphenicol.  
Upon addition of chloramphenicol, a minor but detectable chemical shift change was observed 
for one of the peaks (Figure 4.23), which indicated protein-substrate interaction.  The 
observation of chemical shift perturbations upon the addition of either ethidium bromide or 
chloramphenicol is indicative of properly folded MdfA able to bind its substrates.  Upon 
optimization of NMR conditions, it may be possible to calculate binding constants for these 
MdfA substrates using 
19
F NMR. 
 
.   
Figure 4.23.  One-dimensional NMR spectrum of 5-fluoro-tryptophan-labeled MdfA titrated 
with chloramphenicol.  The chloramphenicol concentrations in the NMR samples are labeled 
beside the corresponding spectra.  The vertical red line marks the position of the peak, which 
shifts at higher concentrations of chloramphenicol. 
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4.9.2. Preliminary NMR Studies of MdfA using 
15
N- and 
15
N, 
13
C, 
2
H- isotope labeling. 
 Preliminary 
1
H, 
15
N-heteronuclear single quantum coherence (HSQC) NMR resulted in 
poor NMR spectra (Figure 4.24).  The chemical shifts for backbone amides and side-chains of 
Asn, Gln, Arg and Trp are observed in the 
1
H, 
15
N-HSQC NMR 2D spectrum (Figure 4.24).  
Fast relaxation of magnetization lead to weak signal and overlap, resulting in poor resolution of 
backbone amide signals.  Poor dispersion of amide signals indicates that the majority of MdfA 
exists in an  helical conformation, consistent with secondary structure prediction (Alder and 
Bibi, 2002).  Comparison of the 1D slices taken through the backbone amide region (Figure 
4.25 (A)) and through the Asn and Gln side-chain region (Figure 4.25 (B)) respectively, shows 
a large difference in the signal-to-noise ratio.  The Asn and Gln side-chain region has a much 
higher signal-to-noise ratio than the backbone amides because the Asn and Gln side-chains are 
likely to have higher mobility than backbone amides in an -helix.  Figure 4.26 is a 1H, 15N-
HSQC spectra of  E. coli subunit c where the NMR signals are well dispersed, and experience 
relatively little overlap.  E. coli subunit c is a very small protein, only 8.3 kDa in size, and 
therefore experiences much slower magnetization relaxation than MdfA in NMR experiments, 
resulting in strong, dispersed NMR signals.  In the study of MdfA, NMR experiments were 
carried out at higher temperatures in order to increase molecular tumbling rate, which in turn 
reduced the overall correlation time.  The shorter correlation time resulted in slower 
magnetization relaxation, which then led to a stronger signal, less overlap and better resolution.  
Optimal temperature for recording 
1
H, 
15
N-HSQC spectra of MdfA was determined to be 37
o
C.  
The spectral overlap seen in the 
15
N-MdfA HSQC spectrum for backbone amides can be 
resolved using 3D HNCO NMR.  The HNCO experiment correlates amide 
1
H and 
15
N chemical 
shifts with the 
13
C chemical shift of the preceding residue.  This addition of the carbonyl 
dimension should resolve the amide peaks in three-dimensions, which would dramatically 
reduce overlap.  In preliminary HNCO experiments for MdfA, around 403 chemical shifts from 
the backbone, and around 30 from Gln and Asn side-chains were expected.  However, only a 
few peaks were observed (data not shown).  This is likely a result of fast relaxation as well.  
The HNCO experiment involves more magnetization transfer steps than HSQC, and therefore 
sensitivity losses due to relaxation are larger than in HSQC. 
66 
 
 
Figure 4.24.  
1
H, 
15
N-HSQC NMR spectra of 
15
N-labeled MdfA in LMPG detergent micelles.  
NMR data was acquired at the National Magnetic Resonance Facility in Madison, Wisconsin 
(NMRFAM) using a 750 MHz Bruker spectrometer with a Cryoprobe.  64 scans were collected 
for every t1 increment, with a total of 64 t1 increments. 
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Figure 4.25.  (A) One-dimensional slice taken through the Asn and Gln side-chain region from 
1
H, 
15
N-HSQC NMR spectra of 
15
N-labeled MdfA.  (B) One-dimensional slice taken through 
the amide backbone region from 
1
H, 
15
N-HSQC NMR spectra of 
15
N-labeled MdfA. Note 
significantly higher signal-to-noise ratio for the side chain signals. 
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Figure 4.26.  
1
H, 
15
N-HSQC NMR spectra of 
15
N-labeled E. coli subunit c in 1-palmitoyl-2-
hydroxy-sn-glycero-3-[phosphor-rac-(1-glycerol)] detergent micelles (Krueger-Koplin et al., 
2004).  NMR data was acquired at 600 MHz.  Reprinted with permission from Springer 
Science+Business Media. 
 
 
The 
13
C-Glu-
15
N-Phe-labeled sample was generated to help solve peak overlap 
problems observed in HNCO data and to conduct substrate binding studies.  Since Phe
27
 
follows Glu
26
 in MdfA, only the Phe
27
 chemical shift would appear in an HNCO NMR 
spectrum of the 
13
C-Glu-
15
N-Phe-labeled MdfA protein.  This experiment would have no peak 
overlap and since Glu
26
 has been implicated in the binding of cationic substrates, the 
13
C-Glu-
15
N-Phe-labeled sample would be ideal for chemical shift perturbation experiments.  If a 
substrate were to interact with Glu
26
, a perturbation in the chemical shift for Phe
27
 would be 
69 
 
observed due to its close proximity to Glu
26
.  Unfortunately, the expected signal of Phe
27
 was 
not detected, possibly due to incomplete labeling. 
4.10. MdfA Activity Detected through Proton Translocation Coupled to ACMA 
Fluorescence   
 In order to determine if MdfA purified in this research is biologically functional, an 
MdfA activity assay was developed.  Purified MdfA was re-incorporated into liposomes for this 
activity assay.  The activity assay uses ACMA fluorescence coupled to proton translocation as 
an indicator of transport activity and is described in detail under the Materials and Methods 
(page 40).  Figure 4.27 shows recorded fluorescence through the course of MdfA activity assay.  
ACMA fluorescence was observed upon the addition of ACMA to the assay solution.  A slight 
drop in fluorescence was observed after the addition of the liposomes and no change in 
fluorescence was observed upon the addition of valinomycin.  An almost complete fluorescence 
quenching was observed after the addition of FCCP, which allows the influx of protons leading 
to the protonation and subsequent sequestering of ACMA resulting in concentration-dependent 
fluorescence quenching.  Increase of ACMA fluorescence was observed upon addition of 
ethidium bromide (Figure 4.28), which indicated proton translocation, and thus MdfA activity 
because proton translocation is coupled to substrate uptake.  Figure 4.28 indicates that the 
increase of ACMA fluorescence observed upon the addition of ethidium bromide was 
concentration dependent.  This activity assay was repeated using chloramphenicol, where a 
chloramphenicol concentration dependent increase in ACMA fluorescence was also observed, 
which indicated proton translocation by MdfA (Figure 4.29).  At the present, the time 
dependence of fluorescence for this assay does not allow for the accurate measurement of the 
initial rates of substrate transport which are necessary to calculate kinetics such as Kt and Vmax.  
However, Kt values for MdfA regarding ethidium bromide and chloramphenicol can be roughly 
estimated from concentration dependence of fluorescence change shown in Figures 4.28 and 
4.29.  The Kt values were estimated to be 1 M - 10 M for ethidium bromide and 1 M - 3 
M for chloramphenicol.  Edgar and Bibi previously determined that E.coli HB101 cells not 
expressing MdfA could withstand the effects of ethidium bromide up to a concentration of 190 
M and chloramphenicol up to a concentration of 6.19 M (Edgar and Bibi, 1997).  The 
estimated Kt of 1 M - 10M for ethidium bromide and 1 M - 3 M for chloramphenicol 
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measured for the purified MdfA are consistent with the protective effect of MdfA-catalyzed 
transport of these drugs in vivo.   
 
 
 
Figure 4.27.  ACMA fluorescence graph for the assay developed for MdfA.   
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Figure 4.28.  Time dependence of ethidium bromide uptake into the MdfA-containing proteo-
liposomes monitored by ACMA fluorescence.  ACMA fluorescence indicates proton 
translocation, which is coupled to ethidium bromide uptake by MdfA.   EtBr concentrations are 
listed to the right. 
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Figure 4.29.  Time dependence of chloramphenicol uptake into the MdfA-containing proteo-
liposomes monitored by ACMA fluorescence.  ACMA fluorescence indicates proton 
translocation, which is coupled to chloramphenicol uptake by MdfA.  Chloramphenicol 
concentrations are listed to the right. 
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5. Discussion  
 The goals of this research project were to develop a practical method for purification of 
MdfA, to evaluate the feasibility of structure determination by NMR and X-ray crystallography, 
and to develop an activity assay for purified MdfA.  MdfA was successfully expressed both in 
the E. coli cell culture and in a cell-free synthesis system.  MdfA was successfully extracted 
from the cell membranes prepared from an overproducing E. coli strain and purified via Ni-
NTA chromatography.  Preliminary X-ray crystallography trials have resulted in several 
potential protein crystals which need to be further investigated.  Initial NMR structural studies 
using 
15
N-, 
15
N, 
13
C, 
2
H- and 
15
N, 
13
C- labeled MdfA samples have found that using NMR to 
investigate the structure of MdfA is feasible, but needs more optimization. 
19
F NMR 
spectroscopy was found to be a potentially useful tool for investigation of substrate binding to 
MdfA and for optimization of sample conditions for high-resolution NMR.  An activity assay 
for the purified MdfA has been developed.  Purified MdfA reconstituted into the liposomes was 
found to actively pump substrates in exchange for protons.   
5.1. MdfA Expression and Purification 
 The gene encoding MdfA was originally cloned into the pBAD vector and the resulting 
vector was named pOD1016 (Dmitriev, unpublished data).  pOD1016 in LMG194 cells was 
found to successfully express mdfA.  In an attempt to increase mdfA expression, pOD1016 was 
modified and expression was tested in different bacterial strains.  The genes encoding both 
thioredoxin and the V5 epitope were deleted from the pOD1016 vector, creating the vector 
pCOG3.  The thioredoxin gene was deleted to determine if the absence of its expression would 
increase mdfA expression and the V5 epitope was deleted because we found that MdfA was 
detectible via its hexa-histidine tail using a pent-histidine antibody.  We found that deleting the 
thioredoxin gene did not result in any higher expression from the pCOG3 vector compared to 
the pOD1016 vector.  However, deleting the V5 epitope resulted in an MdfA product that was 
slightly smaller and better-suited for NMR studies.  Therefore, the pCOG3 vector was used for 
protein expression in this research.  Two strains, LMG194 and C43 (DE3), were tested to 
evaluate mdfA expression.  LMG194 was chosen because it did not metabolize (L)-arabinose 
and because it was capable of growing on minimal media.  C43 (DE3) was chosen because it is 
able to achieve high levels of expression for both toxic and membrane proteins.  MdfA 
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expression levels did not significantly differ between LMG194 and C43 (DE3).  We found that 
a lower (L)-arabinose concentration was required to induce expression in the LMG194 cells 
compared to the C43 (DE3) cells.  Therefore, MdfA was purified from LMG194 cells 
containing the pCOG3 vector.  
LMG194 cells transformed with pCOG3 plasmid were found to successfully express 
mdfA when induced in M63 minimal medium, as well as casamino acid medium, allowing for 
easy uniform labeling in NMR experiments.  The 
15
N-, 
15
N, 
13
C-, 
15
N, 
13
C, 
2
H-, 
13
C-Glu-, 
15
N-
Phe- and 5-fluoro-tryptophan-labeled MdfA samples were subsequently generated by 
expressing mdfA on minimal media supplemented with isotopically-labeled chemicals.   
We attempted to express mdfA in a cell-free synthesis system because it allows for the 
simple generation of selectively-labeled MdfA samples for NMR studies.  The pCOG2 plasmid 
was generated for cell-free synthesis purposes and expressed mdfA at levels near 0.1 mg protein 
per one milliliter reaction mixture, enough to generate samples for NMR studies.  A problem 
that could potentially arise in the cell-free synthesis of membrane proteins is improper folding.  
Addition of liposomes and/or chaperone proteins can aid in proper folding and direct newly 
synthesized proteins into the lipid bilayer.  MdfA has been expressed using cell-free synthesis 
in the presence of liposomes.  However, further investigation is needed to determine if 
functional MdfA was incorporated into the liposomes. 
In order to conduct NMR or X-ray crystallography structural studies on membrane 
proteins, the protein must first be extracted from the cell membrane.  This is commonly 
achieved by employing detergents.  Detergents can displace the lipids around a protein, thereby 
forming a detergent micelle.  Detergents are generally chosen based on cost and suitability.  A 
more affordable detergent can be used for initial purification then replaced with one more 
suitable for NMR experiments.  MdfA was successfully extracted from cell membranes using 
several different detergents.  LMPG was the most efficient at extracting MdfA from cell 
membranes, with over 60% of the MdfA present extracted at a final detergent concentration of 
1.0%.  However, LMPG was not used for extraction after preliminary tests due to its high cost.  
DHPC was chosen as an alternative to LMPG, and provided adequate extraction efficiency, 
extracting around half the MdfA present at a final concentration of 2.0%.  MdfA was also 
successfully extracted using DDM.  DDM is a mild detergent that is often able to preserve 
protein activity and is commonly used in membrane protein crystallization (Banerjee et al., 
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1995; Auer et al., 2001; Boutler and Wang, 2001; Engel et al., 2002).  Several structures have 
been solved for membrane proteins purified in DDM detergent micelles including LacY, EmrD, 
EmrE, and GlpT (Auer et al., 2001; Ambramson et al., 2003; Yin et al., 2006; Korkhov and 
Tate, 2009).  MdfA in DDM detergent micelles has not been used for crystallization trials in 
this work.  However, due to the successful use of DDM in the crystallization of membrane 
proteins, it should not be overlooked in future studies. 
 In order to conduct structural studies via NMR or X-ray crystallography, it is essential 
to obtain protein of 95% purity or higher.  MdfA was successfully purified by Ni-NTA affinity 
chromatography using a hexa-histidine-tag.  The purification method developed in this research 
resulted in 1.0 - 1.4 mg of pure MdfA protein per 1 L bacterial culture, which is significantly 
more than the yield of 0.3 mg per 1 L culture obtained by the purification method developed by 
Sigal (Sigal et al., 2006).  This increase in yield greatly decreases the amount of culture that is 
needed to obtain MdfA in sufficient amount for NMR or X-ray crystallography, and in turn 
greatly reduces the quantities of potentially expensive detergents needed in the purification 
process.  The purified MdfA contained very little contaminating protein according to visual 
inspection of Coomassie-stained and silver-stained SDS-PAGE gels.  The purity of the 
preparation was similar to that obtained previously (Lewinson and Bibi, 2001; Sigal et al., 
2006).  The purification procedure developed by this research is practical, easy, very 
reproducible, and cost effective.    
5.2. Suitability for Structural Studies 
5.2.1. MdfA Stability Optimization  
For structural studies by NMR or X-ray crystallography, high protein stability over time 
is essential.  Crystallization trials can last weeks or months and a single multidimensional NMR 
experiment can last several days.  Initial purification trials resulted in unstable MdfA samples 
that denatured and precipitated within 7 days at 4
o
C (visual observation).  Initially, MdfA was 
purified in TMDG buffer (pH 7.5) containing 0.4% DHPC.  By testing protein stability in a 
variety of solutions with different pH and containing different detergents, conditions were 
found which greatly increased MdfA stability.  LMPG was found to have the largest impact on 
stability.  We compared MdfA stability at 27
o
C in DHPC and LMPG.  Nearly all of the purified 
MdfA precipitated out of the DHPC solution after 72 hours.  In comparison, nearly 100% of the 
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protein remained soluble in LMPG after the same time period.  Investigation of  the pH  effect 
on stability showed that  MdfA was most stable at pH 5 - 6, which is consistent with the 
estimated isoelectric point of 8.85 (Protein Calculator v3.3, 
http://www.scripps.edu/~cdputnam/protcalc.html).  The lower overall net charge in TMDG 
buffer at pH 7.5 could decrease protein solubility as observed in our experiments.  Investigation 
of the effect of sodium chloride showed that MdfA stability was slightly improved in the 
presence of 100 mM NaCl.  Optimal stability was achieved using a 25 mM sodium phosphate 
buffer (pH 6.0), containing 0.2% LMPG and 100 mM NaCl.  After optimization, the MdfA was 
found to be soluble for at least two months at room temperature (visual inspection).  The 
stability of MdfA in solution is suitable for both NMR and X-ray crystallographic studies.    
5.2.2. Investigation of the MdfA Aggregation State 
Monodispersity of a protein solution is extremely important in NMR and X-ray 
crystallography structural studies.  In addition to the MdfA monomer, several prominent extra 
bands were observed via SDS-PAGE of purified MdfA.  Upon further examination, the extra 
bands were determined to be oligomers of MdfA.  Three observations were used to draw that 
conclusion.  First, the extra bands were detected by the anti-penta-histidine antibody used to 
visualize MdfA monomers.  Second, molecular weights corresponding to the extra bands were 
consistent with the dimer, trimer, and tetramer of MdfA, respectively.  Third, relative band 
intensity strongly depended on sample treatment temperature.  If the extra bands were 
contaminating proteins, they would likely have similar relative intensities at all tested 
temperatures. Based on these experiments, pure MdfA has a strong tendency to aggregate at 
elevated temperatures.  These aggregates were stable even in the presence of 6 M urea in the 
loading buffer and SDS-polyacrylamide gel.  Formation of stable aggregates that do not 
dissociate even in the presence of SDS is not uncommon for membrane proteins (Sagne, et al., 
1996).  When MdfA was not exposed to high temperatures prior to loading onto SDS-
polyacrylamide gels, it predominantly migrated as a monomer.   
To investigate the aggregation state of purified MdfA, dynamic light scattering 
experiments were performed demonstrating that MdfA behaved in a monodisperse manner up 
to the protein concentration of 4 mg/mL in DDM, DHPC, and LMPG micelles at temperatures 
up to 30
o
C.  The particle size distribution in the dynamic light scattering experiments was 
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between 3 - 4 nm, which is a reasonable estimate for the 47 kDa MdfA in the detergent micelle.  
Since MdfA behaves in a monodisperse manner, it is suitable for NMR experiments and X-ray 
crystallization trials. 
5.3. Functional Studies 
 In order to determine if the extracted and purified MdfA remained correctly folded and 
functional, substrate binding and transport were investigated.  
19
F NMR experiments were used 
to investigate substrate binding and an MdfA activity assay was developed to investigate 
substrate transport.   
5.3.1. Substrate Binding by 
19
F NMR 
There are several advantages to using 
19
F NMR.  One advantage is that this variant of 
selective labeling can greatly simplify the NMR spectra of large proteins.  Another advantage is 
that this 100% naturally occurring isotope (
19
F) has a spin of one-half and a high magnetogyric 
ratio, making it very sensitive to NMR detection, second only to 
1
H.  As well, the nonexistence 
of naturally occurring fluorine atoms in protein results in 
19
F protein NMR studies with no 
background signal interference.  Another advantage is the low cost of generating fluorine 
labeled protein samples.  When conducting NMR experiments on differently-labeled MdfA 
protein samples, we found that the 
19
F NMR experiment resulted in a spectrum with the least 
overlap and a few nearly distinguishable peaks.  Chemical shift perturbation experiments were 
conducted to determine if solubilized MdfA was able to bind its substrates.  Upon addition of 
MdfA substrates ethidium bromide and chloramphenicol, minor changes in the chemical shifts 
were observed, suggesting that MdfA interacted with these substrates.  However, due to peak 
overlap and corresponding broad peaks in the NMR spectra, it was not possible to calculate 
accurate binding constants for these experiments.  
19
F NMR remains an attractive approach for 
substrate binding studies and NMR sample optimization experiments.  Potentially very high 
sensitivity of 
19
F-NMR is compromised by the outdated design of the available 
19
F NMR 
probes that are no match for modern probes with 
1
H-detection, developed specifically for 
protein NMR.   
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5.3.2. MdfA Activity Detected by ACMA Fluorescence  
The transport of substrates by multidrug transporters has been mostly studied in vivo.  
This usually involves over-expression of the protein of interest to determine which drugs 
become less effective as a result of the protein expression.  A simple in vitro assay was 
developed, which can potentially be used to study substrate specificity for all multidrug 
transporters driven by transmembrane proton gradients.  This assay detects transport of 
substrates into liposomes by tracking the movement of protons via monitoring of the internal 
liposomal pH using ACMA fluorescence.  Using this assay we determined that purified MdfA 
re-incorporated into liposomes bound its substrates ethidium bromide and chloramphenicol, and 
transported them into the liposomes in exchange for protons.  At the present, the long time 
dependence of fluorescence for this assay does not allow for the accurate measurement of the 
initial rates of substrate transport which are necessary to calculate kinetics such as Kt and Vmax.  
The long time dependence may be improved by using lower buffer concentration inside the 
liposomes to increase the magnitude of pH-change resulting from drug uptake.  The highest 
tolerated drug concentrations for E. coli without artificial over-expression of MdfA were 
determined to be about 200 M for ethidium bromide and about 6 M for chloramphenicol 
(Edgar and Bibi, 1997).  Thus, the estimated Kt values of 1 - 10 M for ethidium bromide and 1 
- 3 M for chloramphenicol in vitro are consistent with the protective effect of MdfA in vivo. 
When the activity assay was carried out in proteoliposomes lacking substrates, a small 
rise in fluorescence was observed, indicating a proton leak from the liposomes.  There are 
several possible explanations for this phenomenon.  One possibility is that the proteoliposomes 
are destabilized by the addition of MdfA, leading to nonspecific increase in ion permeability.  
Another possibility is the slow rate of proton transport observed without the substrate can be 
accounted for by the intrinsic Na
+
/H
+
-activity of MdfA.  MdfA could be pumping H
+
 out of the 
liposome in exchange for Na
+
, which would result in the small rise of fluorescence.  MdfA is 
also believed to have intrinsic K
+
/H
+
 -activity.  However, we did not see any indications of 
K
+
/H
+ 
antiport by MdfA in our transport assay. 
 The time dependence of fluorescence for this assay at present does not allow for the 
accurate measurement of the initial rates of substrate transport which are necessary to calculate 
kinetics such as Kt and Vmax, but it holds a lot of promise for future studies.  Once this activity 
assay is optimized, MdfA substrate binding and pumping can be studied in greater detail.  This 
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assay could also be used for other multidrug transporters which use proton gradients to 
facilitate transport.   
5.4. Initial Structural Studies 
5.4.1. Initial Crystallization Screening 
 High-throughput crystallization screening of MdfA purified in LMPG was conducted at 
the Hauptman-Woodward Medical Research Institute in Buffalo, NY.  This screening process 
tests over 1500 conditions in a one month period.  Initial screens yielded several sets of 
conditions that produced crystals.  These conditions were reproduced in our laboratory, but 
unfortunately, none of the crystals were found to consist of protein.  Further microbatch 
screening using the MPD Suite (Qiagen) resulted in two sets of conditions yielding crystals.  
MPD has been used in the crystallization of several membrane proteins (Raman et al., 2006).  
The crystals took up the dye Ponceau S, indicating that the crystals likely contained protein. 
These conditions are being optimized further to obtain larger crystals, which will be tested by 
X-ray diffraction to determine if they contain protein.  If the crystals are not made up of protein, 
there are several options available for further crystallization trials.  One option in membrane 
protein crystallization is to test different detergent micelles.  A commonly used detergent in 
membrane crystallography is DDM, and it has been successfully used in the crystallization of 
several MFS transporters, including EmrD, GlpT and LacY (Abramson et al., 2003; Huang et 
al., 2003; Yin et al., 2006).  MdfA has been successfully extracted and purified using the 
detergent DDM which could be the next step in crystal screening.  Another option in membrane 
protein crystal screening is to use the in-meso screening method (Cherezov et al., 2002).  The 
in-meso method makes use of a lipidic mesophase as the hosting medium and protein reservoir 
from which protein crystals grow (Caffery and Cherezov, 2009).  This method is similar to 
typical crystal screening where similar screening conditions are used.  The use of this method 
will eliminate the presence of detergents in the crystallization process since the protein is 
present in a lipidic mesophase instead of a detergent micelle, and the crystals themselves will 
grow in the lipidic mesophase.   
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5.4.2. Initial Structural Studies by NMR Spectroscopy 
 To date, there are only approximately 30 unique membrane protein structures that have 
been determined using NMR spectroscopy (http://www.drorlist.com/nmr/MPNMR.html, 
September 30, 2009).  Many of the alpha-helical NMR structures are of small polypeptides of 4 
kDa to 10 kDa in size.  However, there are several structures of alpha-helical proteins solved 
which range in size from 30 kDa to 71 kDa including the structure for the 43 kDa homotrimer 
Diacylglycerol Kinase and the 71 kDa homotetramer KcsA (Introduction, page 21).  Thus far, 
NMR spectroscopy was carried out on 
15
N-, 
15
N, 
13
C- and 
15
N, 
13
C, 
2
H-labeled MdfA samples 
to determine the feasibility of high-resolution studies by NMR.  From our results, we 
determined that high-resolution NMR studies on MdfA are feasible.  Not only have we 
developed an expression system capable of generating sufficient amounts of stable uniform 
isotopically labeled- MdfA, we have also obtained NMR spectra which are of the initial quality 
that can be expected for a mostly alpha-helical protein of this size in detergent micelles.  The 
NMR spectra have poor resolution resulting in signal overlap which is likely a result of the fast 
relaxation of magnetization caused by the large size of MdfA and its detergent micelle.  
However, it is possible to reduce relaxation of magnetization by lowering the overall size of 
MdfA and its micelle.  This can be achieved by purifying MdfA using organic solvent-water 
mixtures as alternatives to detergents.  Several biologically-relevant structures have been solved 
for membrane proteins purified in organic solvent-water mixtures using NMR spectroscopy 
including subunit c from ATP synthase (Girvin et al., 1998) and a partial structure of subunit a 
from ATP synthase (Dmitriev et al., 2008).  Signal overlap can also be resolved by three-
dimensional experiments like HNCO and can be further resolved by using three-dimensional 
experiments in conjunction with amino acid selective labeling and/or TROSY experiments.   
The 
19
F NMR experiments which were carried out during this research project can be 
used to optimize sample preparation for NMR experiments.  
19
F NMR is a good choice for 
optimization because of the low cost of labeling.  Several overlapping peaks were observed in 
the 
19
F NMR experiments for 5-fluoro-tryptophan-labeled MdfA where 10 distinct peaks were 
expected.  The optimization of NMR conditions can be evaluated by monitoring the linewidth 
of tryptophan signals.  When the linewidths are at their narrowest, the optimal conditions will 
be met.  These conditions can then be applied to the multidimensional NMR experiments 
required for structural studies. 
80 
 
6. Conclusions and Future Work  
6.1. Conclusions  
 MdfA was successfully over-expressed, extracted from the bacterial membrane using 
non-denaturing detergents, and subsequently purified by Ni-NTA chromatography.  MdfA was 
also successfully expressed in a cell-free synthesis system, paving the way for the selective 
isotope labeling which is needed for NMR studies. The folding properties and activity of MdfA 
prepared in a cell-free system remains to be determined.  The sample conditions for MdfA have 
been optimized for maximum stability and the protein preparation was found to behave in a 
monodisperse manner in solution, making MdfA suitable for initial structural studies.  
Preliminary 
19
F NMR studies indicated that the purified MdfA protein interacted with the 
substrates ethidium bromide and chloramphenicol.  Proper folding and function of purified 
MdfA was revealed through the ACMA fluorescence rebounding assay.  Initial NMR studies of 
MdfA indicate that high-resolution NMR studies are feasible, but further sample optimization is 
needed.  Crystallization trials for MdfA have yielded two conditions which have generated 
potential protein crystals.  X-ray crystallography is likely better suited than NMR for structural 
determination of MdfA.  However, NMR is suitable for substrate binding studies, protein 
dynamic analysis, and possibly global fold determination. 
6.2. Future Work 
 Cell-free synthesis of MdfA should be optimized and examined in the presence of either 
liposomes or detergents to ensure proper folding.  Proper folding can be determined by 
detecting MdfA activity using the coupled proton transport assay developed for this study.  
Once proper folding has been established, selective amino acid labeling of MdfA should be 
investigated and NMR experiments should follow to determine the feasibility of this approach 
for mapping the drug binding site.   
 Optimization of NMR experiments for MdfA needs to be accomplished. The initial 
optimization of sample conditions for NMR experiments can be done using the 5-fluoro-
tryptophan-labeled MdfA to record 
19
F spectra and assess linewidth of tryptophan signals.  The 
multidimensional NMR spectra need to be improved in order to obtain information about the 
structure of MdfA.  The alteration of experimental conditions, testing different buffers and  
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detergents, or using organic solvents in place of detergents, selective isotope labeling, and 
possibly carrying out NMR experiments at the higher magnetic field of 900 MHz could 
improve NMR spectra.  It would be extremely valuable to conduct TROSY experiments on the 
new 1000 MHz NMR spectrometer developed by Bruker, because the optimal field strength for 
TROSY is between 950-1050 MHz (Wider and Wuthrich, 1999).   The first 1000 MHz NMR 
spectrometer was installed at the Centre de RMN à Très Hauts Champs in Lyon, France in 
August 2009.   
The activity assay requires further optimization to improve the speed of the assay.  
Altering buffer component concentrations, liposome concentration, liposome size, and MdfA 
concentration may all improve the speed of this assay.  The optimization will allow for accurate 
kinetic measurements for any proton/drug antiporter.   
 The X-ray crystallographic studies on MdfA are promising and should continue.  If the 
recently discovered crystals do not turn out to consist of protein, MdfA should be purified in 
several different detergents and analyzed by large scale crystallization trials in attempts to 
obtain protein crystals.  Membrane proteins have been successfully crystallized using DDM and 
this would therefore be a good starting point (Yin et al., 2006).  Another option is to use in-
meso screening method which is done in liposomes, therefore eliminating detergents from the 
crystal screens. 
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